

Centre of Evidence Based Dermatology

Systematic reviews on psoriasis

This mapping by topic has systematic reviews published (as final journal publication) from 2012 onwards, plus all the most recent versions of relevant Cochrane Reviews. Conference abstracts are not included.

Last search date: 1st May 2018

CONTENTS

Epidemiology and aetiology

- Prevalence
- Biochemical markers
- Risk factors – genetic
- Risk factors - other
- Infections & colonisation
- Psoriatic arthritis as co-morbidity
- Co-morbidities –cardiovascular
- Co-morbidities – diabetes & metabolic syndrome
- Co-morbidities – psychiatric and psychological/social well being
- Co-morbidities – other
- Diagnosis & evaluation
- Outcome measures
- Disease impact & quality of life
- Economic burden
- Service delivery
- Research methodology

Paediatric psoriasis

- Paediatric psoriasis

Psoriasis in difficult-to-treat sites

- Nail psoriasis
- Scalp psoriasis
- Acral psoriasis
- Flexural psoriasis

Specific psoriasis phenotypes

- Pustular psoriasis
- Guttate psoriasis

Therapies in general

Therapies in general – economic evaluation
Therapies in general – patient preferences
Therapies in general – adherence

Topical treatments

Topical treatments - general
Topical combination treatments
Topical corticosteroids
Topical vitamin D analogues
Topilad dithranol
Topical retinoids
Topical coal tar
Emollients and keratolytics
Topical urea
Other topical treatments

Phototherapy

Phototherapy
Laser therapy

Systemic treatments in general

Systemic treatments in general

Conventional (non-biologic) systemic therapies

Methotrexate
Ciclosporin
Systemic retinoids
Colchicine
Fumaric acid esters
Antibiotics
Thiazolidinediones
Statins
Lactoferrin
Omega-3 fatty acids

Systemic biologic therapies

Biologics & small molecule inhibitors in general – efficacy & safety
Biologics – immunogenicity, treatment failure & treatment regimens
Biologics – risk of infections
Biologics – effect on co-morbidities
Biosimilars

Anti-TNF agents

Anti-TNF agents - general
Anti-TNF agents - induced psoriasis
Anti-TNF agents - etanercept

Anti-TNF agents - infliximab

Anti-TNF agents – adalimumab

Interleukin antagonists

Interleukin antagonists - general

Interleukin antagonists - ustekinumab

Interleukin antagonists - secukinumab

Interleukin antagonists - ixekizumab

Interleukin antagonists - brodalumab

Interleukin antagonists - tildrakizumab

New small molecule systemic therapies

Small molecules - general

Phosphodiesterase-4 inhibitors - apremilast

Janus kinase inhibitors - general

Janus kinase inhibitors - tofacitinib

Combination therapies

Combination therapies

Other treatments

Psychological & educational interventions

Weight loss

Diet & supplements

Tonsillectomy

Herbal medicine (including Chinese herbal medicine)

Other complementary & alternative therapies

Epidemiology and aetiology

Prevalence

Psoriasis in Latin America and the Caribbean: A systematic review.

Hernández-Vásquez A, Molinari L, Larrea N, Ciapponi A.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1991-1998. doi: 10.1111/jdv.14393. Epub 2017 Jul 12.

A systematic review of worldwide epidemiology of psoriasis.

Michalek IM, Loring B, John SM.

J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212. doi: 10.1111/jdv.13854. Epub 2016 Aug 30.

The epidemiology of childhood psoriasis: A scoping review.

Burden-Teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R.

Br J Dermatol. 2016 Jun;174(6):1242-57. doi: 10.1111/bjd.14507. Epub 2016 May 22.

The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions.

Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, Marks R, Naldi L, Weinstock MA, Wulf SK, Michaud C, J L Murray C, Naghavi M.

J Invest Dermatol. 2014 Jun;134(6):1527-34. doi: 10.1038/jid.2013.446. Epub 2013 Oct 28.

Global epidemiology of psoriasis: A systematic review of incidence and prevalence.

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbiditiTy (IMPACT) project team.

J Invest Dermatol. 2013 Feb;133(2):377-85. doi: 10.1038/jid.2012.339. Epub 2012 Sep 27.

Biochemical markers

Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis.

Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG.

Br J Dermatol. 2018 Feb 12. doi: 10.1111/bjd.16437. [Epub ahead of print]

Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis.

Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, An J, Ma H.

Oncotarget. 2017 Nov 1;9(1):1266-1278. doi: 10.18632/oncotarget.22260. eCollection 2018 Jan 2.

Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: a meta-analysis.

Lee YH, Song GG.

Clin Exp Dermatol. 2018 Jan 16. doi: 10.1111/ced.13381. [Epub ahead of print]

Serum leptin, resistin, and adiponectin concentrations in psoriasis: A meta-analysis of observational studies.

Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG.

Dermatology. 2017;233(5):378-389. doi: 10.1159/000481882. Epub 2017 Dec 13.

[Association between circulating prolactin levels and psoriasis and its correlation with disease severity: a meta-analysis.](#)

Lee YH, Song GG.

Clin Exp Dermatol. 2018 Jan;43(1):27-35. doi: 10.1111/ced.13228. Epub 2017 Sep 22.

[Association between plasma interleukin-17 levels and risk of psoriasis: A meta-analysis.](#)

Zhou XY, Bao J, Huang B, Jin Y.

Clin Exp Dermatol. 2017 Mar;42(2):161-166. doi: 10.1111/ced.13033. Epub 2016 Dec 7.

[Role of an imbalanced miRNAs axis in pathogenesis of psoriasis: novel perspectives based on review of the literature.](#)

Wang MJ, Xu YY, Huang RY, Chen XM, Chen HM, Han L, Yan YH, Lu CJ.

Oncotarget. 2017 Jan 17;8(3):5498-5507. doi: 10.18632/oncotarget.12534.

[Immune signatures in patients with psoriasis vulgaris of blood-heat syndrome: A systematic review and meta-analysis.](#)

Li X, Xiao QQ, Li FL, Xu R, Fan B, Wu MF, Zhou M, Li S, Chen J, Peng SG, Li B.

Evid Based Complement Alternat Med. 2016;2016:9503652. doi: 10.1155/2016/9503652. Epub 2016 May 4.

[A systematic review of the role of interleukin-17 and the interleukin-20 family in inflammatory allergic skin diseases.](#)

Hofmann MA, Kiecker F, Zuberbier T.

Curr Opin Allergy Clin Immunol. 2016 Oct;16(5):451-7. doi: 10.1097/ACI.0000000000000310.

[Association of serum uric acid levels in psoriasis: A systematic review and meta-analysis.](#)

Li X, Miao X, Wang H, Wang Y, Li F, Yang Q, Cui R, Li B.

Medicine (Baltimore). 2016 May;95(19):e3676. doi: 10.1097/MD.00000000000003676.

[An exploration of the role of microRNAs in psoriasis: A systematic review of the literature.](#)

Huang RY, Li L, Wang MJ, Chen XM, Huang QC, Lu CJ.

Medicine (Baltimore). 2015 Nov;94(45):e2030. doi: 10.1097/MD.0000000000002030.

[Increased serum resistin levels correlate with psoriasis: A meta-analysis.](#)

Huang H, Shen E, Tang S, Tan X, Guo X, Wang Q, Ding H.

Lipids Health Dis. 2015 May 16;14:44. doi: 10.1186/s12944-015-0039-9.

[Leptin levels in patients with psoriasis: A meta-analysis.](#)

Zhu KJ, Zhang C, Li M, Zhu CY, Shi G, Fan YM.

Clin Exp Dermatol. 2013 Jul;38(5):478-83. doi: 10.1111/ced.12171.

[Adiponectin levels in patients with psoriasis: A meta-analysis.](#)

Zhu KJ, Shi G, Zhang C, Li M, Zhu CY, Fan YM.

J Dermatol. 2013 Jun;40(6):438-42. doi: 10.1111/1346-8138.12121. Epub 2013 Mar 12.

Risk factors – genetic

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

Epigenetics of psoriatic disease: A systematic review and critical appraisal.

Pollock RA, Abji F, Gladman DD.

J Autoimmun. 2017 Mar;78:29-38. doi: 10.1016/j.jaut.2016.12.002. Epub 2016 Dec 10.

Update on the association between interleukin-12 p40 gene polymorphism and risk of psoriasis: A meta-analysis.

Zhao Z., Xie F, Zhang X, Yang J, Wang R, Yang R, Li H.

Dermatologica Sinica 2016;34(3):126-30.

The common CARD14 gene missense polymorphism rs11652075 (c.C2458T/p.Arg820Trp) is associated with psoriasis: A meta-analysis.

Shi G, Li SJ, Wang TT, Cheng CM, Fan YM, Zhu KJ.

Genet Mol Res. 2016 Aug 19;15(3). doi: 10.4238/gmr.15038357.

Meta-analysis of IL-6 -174G/C polymorphism and psoriasis risk.

Nie G, Xie CL, Cao YJ, Xu MM, Shi X, Zou AL, Qi JH.

Genet Mol Res. 2016 Jul 14;15(2). doi: 10.4238/gmr.15028255.

Association between rs6887695 and 3'-untranslated region polymorphisms within the interleukin-12B gene and susceptibility to autoimmune diseases in Asian and European population: A meta-analysis.

Xiao JP, Wang XR, Zhang S, Wang HY, Ye L, Pan HF, Wang DG.

Autoimmunity. 2016 Jun;49(4):277-84. doi: 10.3109/08916934.2016.1166215. Epub 2016 Apr 12.

Association between methylenetetrahydrofolate reductase C677T polymorphism and psoriasis: A meta-analysis.

Wu D, Shi D, Yang L, Zhu X.

J Dermatol. 2016 Feb;43(2):162-9. doi: 10.1111/1346-8138.13039. Epub 2015 Jul 27.

Vascular endothelial growth factor gene polymorphisms and psoriasis susceptibility: A meta-analysis.

Lee YH, Song GG.

Genet Mol Res. 2015 Nov 19;14(4):14396-405. doi: 10.4238/2015.November.18.3.

Lack of association between cytotoxic T-lymphocyte antigen-4+49A/G polymorphism and psoriasis and vitiligo: A meta-analysis of case-control studies.

Liang J, Zhang S, Luo Q, Li W, Tian X, Zhang F, Zhao T, Chen X, Zhang X.

Gene. 2015 Sep 1;568(2):196-202. doi: 10.1016/j.gene.2015.05.051. Epub 2015 May 24.

Polymorphism of VEGF gene in susceptibility to chronic immune-mediated inflammatory diseases: a meta-analysis.

Wei N, Chen Z, Xue Z, Zhu Y.

Rheumatol Int. 2015 Aug;35(8):1351-60. doi: 10.1007/s00296-015-3279-0. Epub 2015 May 26.

The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis.

Song GG, Bae SC, Kim JH, Lee YH.

J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):195-202. doi: 10.1177/1470320313478285.

Association between MTHFR 677C/T polymorphism and psoriasis risk: A meta-analysis.

Qi JH, Qi JH, Shi N, Chen YJ, Nie G.
Genet Mol Res. 2015 Apr 22;14(2):3869-76. doi: 10.4238/2015.April.22.16.

[Association of the late cornified envelope-3 genes with psoriasis and psoriatic arthritis: A systematic review.](#)

Shen C, Gao J, Yin X, Sheng Y, Sun L, Cui Y, Zhang X.
J Genet Genomics. 2015 Feb 20;42(2):49-56. doi: 10.1016/j.jgg.2015.01.001. Epub 2015 Jan 10.

[Evaluation of the association between CD143 gene polymorphism and psoriasis.](#)

Xia T, Diao J, Huang H, Li J, Sun L, Li H, Lv S.
Cell Biochem Biophys. 2014 Dec;70(3):1617-23. doi: 10.1007/s12013-014-0104-4.

[Investigation of the association between psoriasis and human leucocyte antigens A by means of meta-analysis.](#)

Zhao YE, Hu L, Ma JX, Xiao SX, Zhao YL.
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):355-69. doi: 10.1111/jdv.12256. Epub 2013 Aug 24.

[Four polymorphisms of VEGF \(+405C>G, -460T>C, -2578C>A, and -1154G>A\) in susceptibility to psoriasis: a meta-analysis.](#)

Qi M, Huang X, Zhou L, Zhang J.
DNA Cell Biol. 2014 Apr;33(4):234-44. doi: 10.1089/dna.2013.2252.

[Associations between the major histocompatibility complex class I chain-related gene A transmembrane \(MICA-TM\) polymorphism and susceptibility to psoriasis and psoriatic arthritis: A meta-analysis.](#)

Song GG, Kim JH, Lee YH.
Rheumatol Int. 2014 Jan;34(1):117-23. doi: 10.1007/s00296-013-2849-2. Epub 2013 Aug 22

[Associations between tumor necrosis factor- \$\alpha\$ polymorphisms and risk of psoriasis: A meta-analysis.](#)

Zhuang L, Ma W, Cai D, Zhong H, Sun Q.
PLoS One. 2013 Dec 4;8(12):e68827. doi: 10.1371/journal.pone.0068827. eCollection 2013.

[Association of the tumour necrosis factor- \$\alpha\$ polymorphisms rs361525 and rs1800629 with susceptibility to psoriasis: A meta-analysis.](#)

Jia Y, Qin HJ, Zhang JX, Liu XL, Li LJ.
Clin Exp Dermatol. 2013 Dec;38(8):836-44. doi: 10.1111/ced.12136.

[Meta-analysis of the association between psoriasis and human leucocyte antigen-B.](#)

Zhao YE, Ma JX, Hu L, Xiao SX, Zhao YL.
Br J Dermatol. 2013 Aug;169(2):417-27. doi: 10.1111/bjd.12387.

[Associations between interleukin-23R and interleukin-12B polymorphisms and psoriasis susceptibility: A meta-analysis.](#)

Lee YH, Song GG.
Immunol Invest. 2013;42(8):726-36. doi: 10.3109/08820139.2013.810241. Epub 2013 Jul 11.

[Meta-analysis of IL12B polymorphisms \(rs3212227, rs6887695\) with psoriasis and psoriatic arthritis.](#)

Zhu KJ, Zhu CY, Shi G, Fan YM.
Rheumatol Int. 2013 Jul;33(7):1785-90. doi: 10.1007/s00296-012-2637-4. Epub 2013 Jan 8.

[Apal, BsmI, FokI and TaqI polymorphisms in the vitamin D receptor \(VDR\) gene and the risk of psoriasis: A meta-analysis.](#)

Liu JL, Zhang SQ, Zeng HM.

J Eur Acad Dermatol Venereol. 2013 Jun;27(6):739-46. doi: 10.1111/j.1468-3083.2012.04553.x. Epub 2012 Apr 28.

[Angiotensin-converting enzyme gene polymorphisms and the risk of psoriasis: a meta-analysis.](#)

Liu T, Han Y, Lu L.

Clin Exp Dermatol. 2013 Jun;38(4):352-8; quiz 359. doi: 10.1111/ced.12106.

[Single nucleotide polymorphisms in the tumor necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and psoriatic arthritis: A meta-analysis.](#)

Zhu J, Qu H, Chen X, Wang H, Li J.

PLoS One. 2013 May 23;8(5):e64376. doi: 10.1371/journal.pone.0064376. Print 2013.

[Meta-analysis of vitamin D receptor polymorphisms and psoriasis risk.](#)

Stefanic M, Rucevic I, Barisic-Drusko V.

Int J Dermatol. 2013 Jun;52(6):705-10. doi: 10.1111/j.1365-4632.2012.5813.x. Epub 2013 Mar 14.

[CD226 Gly307Ser association with multiple autoimmune diseases: a meta-analysis.](#)

Qiu ZX, Zhang K, Qiu XS, Zhou M, Li WM.

Hum Immunol. 2013 Feb;74(2):249-55. doi: 10.1016/j.humimm.2012.10.009. Epub 2012 Oct 13.

[Apolipoprotein E gene polymorphism in psoriasis: A meta-analysis.](#)

Han Y, Liu T, Lu L.

Arch Med Res. 2013 Jan;44(1):46-53. doi: 10.1016/j.arcmed.2012.10.009. Epub 2012 Nov 6.

[Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis.](#)

Zhu KJ, Zhu CY, Shi G, Fan YM.

Inflamm Res. 2012 Oct;61(10):1149-54. doi: 10.1007/s00011-012-0509-8. Epub 2012 Jun 17.

[Association of STAT4 rs7574865 polymorphism with autoimmune diseases: A meta-analysis.](#)

Liang YL, Wu H, Shen X, Li PQ, Yang XQ, Liang L, Tian WH, Zhang LF, Xie XD.

Mol Biol Rep. 2012 Sep;39(9):8873-82. doi: 10.1007/s11033-012-1754-1. Epub 2012 Jun 20.

[PTPN22 C1858T and the risk of psoriasis: a meta-analysis.](#)

Chen YF, Chang JS.

Mol Biol Rep. 2012 Aug;39(8):7861-70. doi: 10.1007/s11033-012-1630-z. Epub 2012 Apr 28.

[Meta-analysis of NOD2/CARD15 polymorphisms with psoriasis and psoriatic arthritis.](#)

Zhu K, Yin X, Tang X, Zhang F, Yang S, Zhang X.

Rheumatol Int. 2012 Jul;32(7):1893-900. doi: 10.1007/s00296-011-1813-2. Epub 2011 Mar 30.

[Associations between interleukin-10 polymorphisms and susceptibility to psoriasis: A meta-analysis.](#)

Lee YH, Choi SJ, Ji JD, Song GG.

Inflamm Res. 2012 Jul;61(7):657-63. doi: 10.1007/s00011-012-0458-2. Epub 2012 Mar 18.

Risk factors - other

[Association between Vitamin D deficiency and psoriasis: An exploratory study.](#)

Al-Dhubaibi MS.

Int J Health Sci (Qassim). 2018 Jan-Feb;12(1):33-9.

[Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies.](#)

Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ.

Eur J Epidemiol. 2018 Apr 21. doi: 10.1007/s10654-018-0366-z. [Epub ahead of print]

[The associations between psychological stress and psoriasis: a systematic review.](#)

Stewart TJ, Tong W, Whitfeld MJ.

Int J Dermatol. 2018 Mar 8. doi: 10.1111/ijd.13956. [Epub ahead of print]

[Psychological stress and psoriasis. A systematic review and meta-analysis.](#)

Snast I, Reiter O, Atzmony L, Leshem YA, Hodak E, Mimouni D, Pavlovsky L.

Br J Dermatol. 2017 Nov 9. doi: 10.1111/bjd.16116. [Epub ahead of print]

[Patients with schizophrenia have a higher risk of psoriasis: A systematic review and meta-analysis.](#)

Ungprasert P, Wijarnpreecha K, Cheungpasitporn W.

Psychiatry Res. 2018 Jan;259:422-426. doi: 10.1016/j.psychres.2017.11.021. Epub 2017 Nov 7.

[The association of autoimmune thyroid disease \(AITD\) with psoriatic disease: A prospective cohort study, systematic review and meta-analysis.](#)

Khan SR, Bano A, Wakkee M, Korevaar T, Franco O, Nijsten T, Peeters RP, Chaker L.

Eur J Endocrinol. 2017 Oct;177(4):347-359. doi: 10.1530/EJE-17-0397. Epub 2017 Jul 26.

[Periodontitis and risk of psoriasis: A systematic review and meta-analysis.](#)

Ungprasert P, Wijarnpreecha K, Wetter DA.

J Eur Acad Dermatol Venereol. 2017 May;31(5):857-862. doi: 10.1111/jdv.14051. Epub 2016 Dec 7.

[Psoriasis and smoking: A systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity.](#)

Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Gulliver WP, Haraoui B, Bissonnette R.

J Cutan Med Surg. 2016 May;20(3):221-7. doi: 10.1177/1203475415616073. Epub 2015 Nov 9.

[Anti-tumor necrosis factor \$\alpha\$ -related psoriatic lesions in children with inflammatory bowel disease: Case report and systematic literature review.](#)

Romiti R, Araujo KM, Steinwurz F, Denadai R.

Pediatr Dermatol. 2016 Mar-Apr;33(2):e174-8. doi: 10.1111/pde.12820.

[The relationship of obesity with the severity of psoriasis: A systematic review.](#)

Fleming P, Kraft J, Gulliver WP, Lynde C.

J Cutan Med Surg. 2015 Sep-Oct;19(5):450-6. doi: 10.1177/1203475415586332. Epub 2015 May 7.

[A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.](#)

Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M.

Mult Scler. 2015 Mar;21(3):282-93. doi: 10.1177/1352458514564490. Epub 2014 Dec 22.

[Obesity in autoimmune diseases: not a passive bystander.](#)

Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y.

Autoimmun Rev. 2014 Sep;13(9):981-1000. doi: 10.1016/j.autrev.2014.07.001. Epub 2014 Aug 2.

[Psoriasis and smoking: A systematic review and meta-analysis.](#)

Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ.
Br J Dermatol. 2014 Feb;170(2):304-14. doi: 10.1111/bjd.12670

[\[Lithium treatment and potential long-term side effects: A systematic review of the literature\].](#)

Albert U, De Cori D, Blengino G, Bogetto F, Maina G.
Riv Psichiatr. 2014 Jan-Feb;49(1):12-21. doi: 10.1708/1407.15620. Review. Italian.

[Alcohol consumption and psoriasis: A systematic literature review.](#)

Brenaut E, Horreau C, Pouplard C, Barnetche T, Paul C, Richard MA, Joly P, Le Maître M, Aractingi S, Aubin F, Cribier B, Jullien D, Ortonne JP, Misery L.
J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:30-5. doi: 10.1111/jdv.12164

[Autoimmune disease in people with multiple sclerosis and their relatives: A systematic review and meta-analysis.](#)

Dobson R, Giovannoni G.
J Neurol. 2013 May;260(5):1272-85. doi: 10.1007/s00415-012-6790-1. Epub 2013 Jan 12.

[Alcohol consumption and psoriatic risk: A meta-analysis of case-control studies.](#)

Zhu KJ, Zhu CY, Fan YM.
J Dermatol. 2012 Sep;39(9):770-3. doi: 10.1111/j.1346-8138.2012.01577.x. Epub 2012 May 9.

[The coexistence of psoriasis and vitiligo: A review.](#)

Sawchuk M, Spano F, Loo WJ, Guenther L.
J Cutan Med Surg. 2012 Sep-Oct;16(5):300-5.

Infections & colonisation

[Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review.](#)

Thrastardottir T, Jon Love T.
Rheumatol Int. 2017 Nov 9. doi: 10.1007/s00296-017-3873-4. [Epub ahead of print]

[Risks for Staphylococcus aureus colonization in psoriasis patients: A systematic review and meta-analysis.](#)

Ng CY, Huang YH, Chu CF, Wu TC, Liu SH.
Br J Dermatol. 2017 Oct;177(4):967-977. doi: 10.1111/bjd.15366. Epub 2017 Sep 8.

[A systematic review and meta-analysis on Staphylococcus aureus carriage in psoriasis, acne and rosacea.](#)

Totté JE, van der Feltz WT, Bode LG, van Belkum A, van Zuuren EJ, Pasmans SG.
Eur J Clin Microbiol Infect Dis. 2016 Jul;35(7):1069-77. doi: 10.1007/s10096-016-2647-3. Epub 2016 May 5.

[The prevalence of culture-confirmed toenail onychomycosis in at-risk patient populations.](#)

Gupta AK, Daigle D, Foley KA.
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1039-44. doi: 10.1111/jdv.12873. Epub 2014 Nov 21.

[The prevalence of onychomycosis in psoriatic patients: A systematic review.](#)

Klaassen KM, Dulak MG, van de Kerkhof PC, Pasch MC.

J Eur Acad Dermatol Venereol. 2014 May;28(5):533-41. doi: 10.1111/jdv.12239. Epub 2013 Aug 19.

Psoriatic arthritis as co-morbidity

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review.

Thrastardottir T, Jon Love T.

Rheumatol Int. 2017 Nov 9. doi: 10.1007/s00296-017-3873-4. [Epub ahead of print]

Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis.

Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, Beylot-Barry M, Misery L, Joly P, Le Maître M, Aractingi S, Aubin F, Cantagrel A, Ortonne JP, Jullien D.

J Am Acad Dermatol. 2015 Aug;73(2):242-8. doi: 10.1016/j.jaad.2015.05.001. Epub 2015 Jun 6.

Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: A systematic review.

Boehncke WH, Alvarez Martinez D, Solomon JA, Gottlieb AB.

J Rheumatol. 2014 Nov;41(11):2301-5. doi: 10.3899/jrheum.140880.

Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion.

Richard MA, Barnetche T, Rouzaud M, Sevrain M, Villani AP, Aractingi S, Aubin F, Beylot-Barry M, Joly P, Jullien D, Le Maître M, Misery L, Ortonne JP, Cantagrel A, Paul C.

J Eur Acad Dermatol Venereol. 2014 Aug;28 Suppl 5:3-12. doi: 10.1111/jdv.12560.

Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review.

Rouzaud M, Sevrain M, Villani AP, Barnetche T, Paul C, Richard MA, Jullien D, Misery L, Le Maître M, Aractingi S, Aubin F, Joly P, Cantagrel A, Ortonne JP, Beylot-Barry M.

J Eur Acad Dermatol Venereol. 2014 Aug;28 Suppl 5:17-26. doi: 10.1111/jdv.12562.

Co-morbidities –cardiovascular

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Homocysteine: A potential common route for cardiovascular risk and DNA methylation in psoriasis.

Wang WM, Jin HZ.

Chin Med J (Engl). 2017 Aug 20;130(16):1980-1986. doi: 10.4103/0366-6999.211895.

Psoriasis and cardiovascular events: Updating the evidence.

Raaby L, Ahlehoff O, de Thurah A.

Arch Dermatol Res. 2017 Apr;309(3):225-228. doi: 10.1007/s00403-016-1712-1. Epub 2017 Feb 17.

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

Psoriasis increases risk of new-onset atrial fibrillation: A systematic review and meta-analysis of prospective observational studies.

Upala S, Shahnawaz A, Sanguankeo A.

J Dermatolog Treat. 2017 Aug;28(5):406-410. doi: 10.1080/09546634.2016.1255703. Epub 2016 Nov 18.

The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.

Yang ZS, Lin NN, Li L, Li Y.

Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

Psoriasis and risk of incident atrial fibrillation: A systematic review and meta-analysis.

Ungprasert P, Srivali N, Kittanamongkolchai W.

Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5):489-97. doi: 10.4103/0378-6323.186480.

Epicardial fat tissue in patients with psoriasis: A systematic review and meta-analysis.

Wang X, Guo Z, Zhu Z, Bao Y, Yang B.

Lipids Health Dis. 2016 May 31;15:103. doi: 10.1186/s12944-016-0271-y.

Association between psoriasis and subclinical atherosclerosis: A meta-analysis.

Fang N, Jiang M, Fan Y.

Medicine (Baltimore). 2016 May;95(20):e3576. doi: 10.1097/MD.0000000000003576.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: Novel therapeutic insights coming from a meta-analysis of the literature data.

De Vecchis R, Baldi C, Palmisani L.

Anatol J Cardiol. 2016 Jan;16(1):2-9. doi: 10.5152/akd.2015.6136.

Ischemic cardiovascular involvement in psoriasis: A systematic review.

Mosca S, Gargiulo P, Balato N, Di Costanzo L, Parente A, Paolillo S, Ayala F, Trimarco B, Crea F, Perrone-Filardi P.

Int J Cardiol. 2015 Jan 15;178:191-9. doi: 10.1016/j.ijcard.2014.10.092. Epub 2014 Oct 23.

Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

Psoriasis and risk of venous thromboembolism: A systematic review and meta-analysis.

Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P.

QJM. 2014 Oct;107(10):793-7. doi: 10.1093/qjmed/hcu073. Epub 2014 Apr 8.

[Psoriasis beyond the skin: A review of the literature on cardiometabolic and psychological co-morbidities of psoriasis.](#)

Puig L, Kirby B, Mallbris L, Strohal R.
Eur J Dermatol. 2014 May-Jun;24(3):305-11. doi: 10.1684/ejd.2014.2299.

[Subclinical cardiovascular disease in plaque psoriasis: Association or causal link?](#)

Shaharyar S, Warraich H, McEvoy JW, Oni E, Ali SS, Karim A, Jamal O, Blaha MJ, Blumenthal RS, Fialkow J, Cury R, Budoff MJ, Agatston AA, Nasir K.
Atherosclerosis. 2014 Jan;232(1):72-8. doi: 10.1016/j.atherosclerosis.2013.10.023. Epub 2013 Nov 1.

[Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors.](#)

Miller IM, Ellervik C, Yazdanyar S, Jemec GB.
J Am Acad Dermatol. 2013 Dec;69(6):1014-24. doi: 10.1016/j.jaad.2013.06.053.

[Quantifying cardiovascular disease risk factors in patients with psoriasis: A meta-analysis.](#)

Miller IM, Skaaby T, Ellervik C, Jemec GB.
Br J Dermatol. 2013 Dec;169(6):1180-7. doi: 10.1111/bjd.12490.

[Role of psoriasis as independent predictor of cardiovascular disease: A meta-regression analysis.](#)

Gaeta M, Castelvecchio S, Ricci C, Pigatto P, Pellissero G, Cappato R.
Int J Cardiol. 2013 Oct 3;168(3):2282-8. doi: 10.1016/j.ijcard.2013.01.197. Epub 2013 Mar 9.

[Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis.](#)

Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH.
J Invest Dermatol. 2013 Oct;133(10):2340-6. doi: 10.1038/jid.2013.149. Epub 2013 Feb 21.

[Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: A systematic literature review.](#)

Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, Jullien D, Aractingi S, Aubin F, Joly P, Le Maître M, Ortonne JP, Paul C, Richard MA.
J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:12-29. doi: 10.1111/jdv.12163.

[Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials.](#)

Tzellos T, Kyrgidis A, Zouboulis CC.
J Eur Acad Dermatol Venereol. 2013 May;27(5):622-7. doi: 10.1111/j.1468-3083.2012.04500.x. Epub 2012 Mar 8.

[Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies.](#)

Armstrong EJ, Harskamp CT, Armstrong AW.
J Am Heart Assoc. 2013 Apr 4;2(2):e000062. doi: 10.1161/JAH.113.000062.

[The association between psoriasis and hypertension: A systematic review and meta-analysis of observational studies.](#)

Armstrong AW, Harskamp CT, Armstrong EJ.
J Hypertens. 2013 Mar;31(3):433-42; discussion 442-3. doi: 10.1097/HJH.0b013e32835bcce1.

[Examining the risk of cardiovascular disease in patients with psoriasis: a critical review.](#)

Papp K, Poulin Y, Vieira A.
J Cutan Med Surg. 2013 Mar-Apr;17(2):89-105.

[Cardiovascular aspects of psoriasis: An updated review.](#)
Pietrzak A, Bartosińska J, Chodorowska G, Szepietowski JC, Palusziewicz P, Schwartz RA.
Int J Dermatol. 2013 Feb;52(2):153-62. doi: 10.1111/j.1365-4632.2012.05584.x.

[Association of psoriasis with stroke and myocardial infarction: Meta-analysis of cohort studies.](#)
Xu T, Zhang YH.
Br J Dermatol. 2012 Dec;167(6):1345-50. doi: 10.1111/bjd.12002. Epub 2012 Nov 20.

Co-morbidities – diabetes & metabolic syndrome

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Serum leptin, resistin, and adiponectin concentrations in psoriasis: A meta-analysis of observational studies.](#)
Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG.
Dermatology. 2017;233(5):378-389. doi: 10.1159/000481882. Epub 2017 Dec 13.

[Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome.](#)
Rodríguez-Zúñiga MJM, García-Perdomo HA.
J Am Acad Dermatol. 2017 Oct;77(4):657-666.e8. doi: 10.1016/j.jaad.2017.04.1133.

[An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies.](#)
Singh S, Young P, Armstrong AW.
PLoS One. 2017 Jul 18;12(7):e0181039. doi: 10.1371/journal.pone.0181039. eCollection 2017.

[Association of psoriasis and metabolic syndrome in Latin America: A systematic review and meta-analysis.](#)
Rodríguez-Zúñiga MJM, Cortez-Franco F, Quijano-Gomero E.
Actas Dermosifiliogr. 2017 May;108(4):326-334. doi: 10.1016/j.ad.2016.11.009. Epub 2017 Jan 20.
English, Spanish.

[Relationship between psoriasis and metabolic syndrome: A systematic review.](#)
Singh S, Young P, Armstrong AW.
G Ital Dermatol Venereol. 2016 Dec;151(6):663-677. Epub 2016 Sep 2.

Association between psoriasis and metabolic syndrome: A meta-analysis from 12 case control studies.
Jin J.-J. , Zeng S.-W.
Int J Clin Exp Med 2016;9(9):17933-17939.
<http://www.ijcem.com/files/ijcem0031209.pdf>

[Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: A systematic review and meta-analysis.](#)
Coto-Segura P, Eiris-Salvado N, González-Lara L, Queiro-Silva R, Martínez-Cambor P, Maldonado-Seral C, García-García B, Palacios-García L, Gomez-Bernal S, Santos-Juanes J, Coto E.
Br J Dermatol. 2013 Oct;169(4):783-93. doi: 10.1111/bjd.12473.

[Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies.](#)

Armstrong AW, Harskamp CT, Armstrong EJ.

J Am Acad Dermatol. 2013 Apr;68(4):654-62. doi: 10.1016/j.jaad.2012.08.015. Epub 2013 Jan 27.

[Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis.](#)

Armstrong AW, Harskamp CT, Armstrong EJ.

JAMA Dermatol. 2013 Jan;149(1):84-91. doi: 10.1001/2013.jamadermatol.406.

[Psoriasis increased the risk of diabetes: A meta-analysis.](#)

Cheng J, Kuai D, Zhang L, Yang X, Qiu B.

Arch Dermatol Res. 2012 Mar;304(2):119-25. doi: 10.1007/s00403-011-1200-6. Epub 2012 Jan 1.

Co-morbidities – psychiatric and psychological/social well being

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Analysis of the prevalence of mental disorders in psoriasis: The relevance of psychiatric assessment in dermatology.](#)

Ferreira BR, Pio-Abreu JL, Reis JP, Figueiredo A.

Psychiatr Danub. 2017 Dec;29(4):401-406. doi: 10.24869/psyd.2017.401.

[Analysis of the prevalence of mental disorders in psoriasis: The relevance of psychiatric assessment in dermatology.](#)

Ferreira BR, Pio-Abreu JL, Reis JP, Figueiredo A.

Psychiatr Danub. 2017 Dec;29(4):401-406. doi: 10.24869/psyd.2017.401.

[Patients with schizophrenia have a higher risk of psoriasis: A systematic review and meta-analysis.](#)

Ungprasert P, Wijarnpreecha K, Cheungpasitporn W.

Psychiatry Res. 2018 Jan;259:422-426. doi: 10.1016/j.psychres.2017.11.021. Epub 2017 Nov 7.

[Psoriasis and suicidality: A systematic review and meta-analysis.](#)

Singh S, Taylor C, Kornmehl H, Armstrong AW.

J Am Acad Dermatol. 2017 Sep;77(3):425-440.e2. doi: 10.1016/j.jaad.2017.05.019.

[The prevalence of anxiety in patients with psoriasis: A systematic review of observational studies and clinical trials.](#)

Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP.

J Eur Acad Dermatol Venereol. 2017 May;31(5):798-807. doi: 10.1111/jdv.13891. Epub 2016 Sep 12.

[Risk of suicidality in people with psoriasis: A systematic review and meta-analysis of cohort studies.](#)

Chi CC, Chen TH, Wang SH, Tung TH.

Am J Clin Dermatol. 2017 Oct;18(5):621-627. doi: 10.1007/s40257-017-0281-1.

[Psoriasis and sleep disorders: A systematic review.](#)

Gupta MA, Simpson FC, Gupta AK.

Sleep Med Rev. 2016 Oct;29:63-75. doi: 10.1016/j.smrv.2015.09.003. Epub 2015 Sep 21.

[Measurement, classification and evaluation of sleep disturbance in psoriasis: A systematic review.](#)

Henry AL, Kyle SD, Bhandari S, Chisholm A, Griffiths CE, Bundy C.

PLoS One. 2016 Jun 21;11(6):e0157843. doi: 10.1371/journal.pone.0157843. eCollection 2016.

[Psoriasis and associated psychiatric disorders: A systematic review on etiopathogenesis and clinical correlation.](#)

Ferreira BI, Abreu JL, Reis JP, Figueiredo AM.

J Clin Aesthet Dermatol. 2016 Jun;9(6):36-43. Epub 2016 Jun 1.

[Tvc review and meta-analysis of the effect on depression and anxiety.](#)

Abbott R, Whear R, Nikolaou V, Bethel A, Coon JT, Stein K, Dickens C.

J Psychosom Res. 2015 Sep;79(3):175-84. doi: 10.1016/j.jpsychores.2015.04.008. Epub 2015 Apr 23.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis.](#)

Dowlatabadi EA, Wakkee M, Arends LR, Nijsten T.

J Invest Dermatol. 2014 Jun;134(6):1542-51. doi: 10.1038/jid.2013.508. Epub 2013 Nov 27.

[Psoriasis beyond the skin: A review of the literature on cardiometabolic and psychological co-morbidities of psoriasis.](#)

Puig L, Kirby B, Mallbris L, Strohal R.

Eur J Dermatol. 2014 May-Jun;24(3):305-11. doi: 10.1684/ejd.2014.2299.

Co-morbidities – other

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis.](#)

Ungprasert P, Rakasuk S.

Int Urol Nephrol. 2018 Apr 11. doi: 10.1007/s11255-018-1868-z. [Epub ahead of print]

[Association between psoriasis and asthma risk: A meta-analysis.](#)

Wang J, Ke R, Shi W, Yan X, Wang Q, Zhang Q, Chai L, Li M.

Allergy Asthma Proc. 2018 Mar 1;39(2):103-109. doi: 10.2500/aap.2018.39.4109.

[Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.](#)

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.

J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043.

[Relative versus absolute risk of comorbidities in patients with psoriasis.](#)

Saleem MD, Kesty C, Feldman SR.

J Am Acad Dermatol. 2017 Mar;76(3):531-537. doi: 10.1016/j.jaad.2016.11.037. Epub 2016 Dec 13.

[Psoriasis and risk of celiac disease: A systematic review and meta-analysis.](#)

Ungprasert P, Wijarnpreecha K, Kittanamongkolchai W.

Indian J Dermatol. 2017 Jan-Feb;62(1):41-46. doi: 10.4103/0019-5154.198031.

[Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis.](#)

Ungprasert P, Srivali N, Thongprayoon C.

J Dermatolog Treat. 2016 Aug;27(4):316-21. doi: 10.3109/09546634.2015.1107180. Epub 2015 Nov 18.

[Psoriasis and adverse pregnancy outcomes: A systematic review of observational studies.](#)

Bobotsis R, Gulliver WP, Monaghan K, Lynde C, Fleming P.

Br J Dermatol. 2016 Sep;175(3):464-72. doi: 10.1111/bjd.14547. Epub 2016 Jul 24.

[Association of serum uric acid levels in psoriasis: A systematic review and meta-analysis.](#)

Li X, Miao X, Wang H, Wang Y, Li F, Yang Q, Cui R, Li B.

Medicine (Baltimore). 2016 May;95(19):e3676. doi: 10.1097/MD.0000000000003676.

[Risk of Parkinson's disease among patients with psoriasis: A systematic review and meta-analysis.](#)

Ungprasert P, Srivali N, Kittanamongkolchai W.

Indian J Dermatol. 2016 Mar-Apr;61(2):152-6. doi: 10.4103/0019-5154.177771.

[Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis.](#)

Li X, Kong L, Li F, Chen C, Xu R, Wang H, Peng S, Zhou M, Li B.

PLoS One. 2015 Dec 23;10(12):e0145221. doi: 10.1371/journal.pone.0145221. eCollection 2015.

[Family history of autoimmune diseases is associated with an increased risk of autism in children: A systematic review and meta-analysis.](#)

Wu S, Ding Y, Wu F, Li R, Xie G, Hou J, Mao P.

Neurosci Biobehav Rev. 2015 Aug;55:322-32. doi: 10.1016/j.neubiorev.2015.05.004. Epub 2015 May 15.

[Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis.](#)

Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M.

J Eur Acad Dermatol Venereol. 2015 Apr;29(4):656-62. doi: 10.1111/jdv.12847. Epub 2014 Nov 21

[Sexual dysfunction in psoriasis: A systematic review.](#)

Molina-Leyva A, Jiménez-Moleón JJ, Naranjo-Sintes R, Ruiz-Carrascosa JC.

J Eur Acad Dermatol Venereol. 2015 Apr;29(4):649-55. doi: 10.1111/jdv.12845. Epub 2014 Nov 26.

[Diet and psoriasis, part II: celiac disease and role of a gluten-free diet.](#)

Bhatia BK, Millsop JW, Debbaneh M, Koo J, Linos E, Liao W.

J Am Acad Dermatol. 2014 Aug;71(2):350-8. doi: 10.1016/j.jaad.2014.03.017. Epub 2014 Apr 26.

[Risk of cancer in psoriasis: A systematic review and meta-analysis of epidemiological studies.](#)

Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maître M, Ortonne JP, Paul C.

J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:36-46. doi: 10.1111/jdv.12165.

The association between psoriasis and dyslipidaemia: A systematic review.

Ma C, Harskamp CT, Armstrong EJ, Armstrong AW.

Br J Dermatol. 2013 Mar;168(3):486-95. doi: 10.1111/bjd.12101. Epub 2013 Jan 18.

The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies.

Armstrong AW, Harskamp CT, Armstrong EJ.

Nutr Diabetes. 2012 Dec 3;2:e54. doi: 10.1038/nutd.2012.26.

Sexual dysfunction in patients with psoriasis and psoriatic arthritis--a systematic review.

Kurizky PS, Mota LM.

Rev Bras Reumatol. 2012 Dec;52(6):943-8. Review. English, Portuguese.

The coexistence of psoriasis and vitiligo: A review.

Sawchuk M, Spano F, Loo WJ, Guenther L.

J Cutan Med Surg. 2012 Sep-Oct;16(5):300-5.

Diagnosis & evaluation

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Dermoscopy in the diagnosis of inflammatory dermatoses: Systematic review findings reported for psoriasis, lupus, and lichen planus.

Cook LC, Hanna C, Foulke GT, Seiverling EV.

J Clin Aesthet Dermatol. 2018 Apr;11(4):41-42. Epub 2018 Apr 1.

Scaly pink patches: differentiating psoriasis from basal cell carcinoma.

Hanna C, Cook L, Foulke G, Seiverling EV.

Cutis. 2018 Jan;101(1):44-46.

A systematic review of diagnostic criteria for psoriasis in adults and children: Evidence from studies with a primary aim to develop or validate diagnostic criteria.

Burden-Teh E, Phillips RC, Thomas KS, Ratib S, Grindlay D, Murphy R.

Br J Dermatol. 2017 Nov 6. doi: 10.1111/bjd.16104. [Epub ahead of print]

Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: A systematic literature review.

Zabotti A, Bandinelli F, Batticciotto A, Scirè CA, Iagnocco A, Sakellariou G; Musculoskeletal Ultrasound Study Group of the Italian Society of Rheumatology.

Rheumatology (Oxford). 2017 Sep 1;56(9):1518-1532. doi: 10.1093/rheumatology/kex179.

A four-phase strategy for the implementation of reflectance confocal microscopy in dermatology.

Hoogendoorn L, Gerritsen MJ, Wolberink EA, Peppelman M, van de Kerkhof PC, van Erp PE.

J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1308-14. doi: 10.1111/jdv.13627. Epub 2016 Apr 2.

Effects of narrow band ultraviolet B on serum levels of vascular endothelial growth factor and interleukin-8 in patients with psoriasis.

Chen HQ, Li X, Tang R.

Am J Ther. 2016 May-Jun;23(3):e655-62. doi: 10.1097/MJT.0000000000000330.

The value of in vivo reflectance confocal microscopy in the diagnosis and monitoring of inflammatory and infectious skin diseases: a systematic review.

Hoogendoorn L, Peppelman M, van de Kerkhof PC, van Erp PE, Gerritsen MJ.
Br J Dermatol. 2015;172(5):1222-48. doi: 10.1111/bjd.13499. Epub 2015 Mar 19.

Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis.

Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T.
Br J Dermatol. 2013 Aug;169(2):266-82. doi: 10.1111/bjd.12355.

Outcome measures

Reporting of outcomes in randomised controlled trials on nail psoriasis; a systematic review.

Busard CIM, Nolte JYC, Pasch MC, Spuls PI.
Br J Dermatol. 2017 Jul 19. doi: 10.1111/bjd.15831. [Epub ahead of print]

Measuring the impact of dermatological conditions on family and caregivers: A review of dermatology-specific instruments.

Sampogna F, Finlay AY, Salek SS, Chernyshov P, Dalgard FJ, Evers AWM, Linder D, Manolache L, Marron SE, Poot F, Spillekom-van Koulik S, Svensson Å, Szepietowski JC, Tomas-Aragones L, Abeni D; European Academy of Dermatology and Venereology TaskForce on Quality of Life.
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1429-1439. doi: 10.1111/jdv.14288. Epub 2017 May 19.

A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.

Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, Piguet V.
Br J Dermatol. 2017 Mar;176(3):577-593. doi: 10.1111/bjd.14788. Epub 2016 Oct 12.

EQ-5D in skin conditions: An assessment of validity and responsiveness.

Yang Y, Brazier J, Longworth L.
Eur J Health Econ. 2015 Dec;16(9):927-39. doi: 10.1007/s10198-014-0638-9. Epub 2014 Oct 31.

Patient-reported outcome measures in psoriasis: The good, the bad and the missing!

Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C.
Br J Dermatol. 2015;172(5):1210-21. doi: 10.1111/bjd.13691. Epub 2015 Apr 12.

Patient-reported functional health and well-being outcomes with drug therapy: A systematic review of randomized trials using the SF-36 health survey.

Frendl DM, Ware JE Jr.
Med Care. 2014 May;52(5):439-45. doi: 10.1097/MLR.00000000000010311.

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The correlation between disease severity and psychological burden in patients treated with biological therapies.

Mattei PL, Corey KC, Kimball AB.
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7. doi: 10.1111/jdv.12106. Epub 2013 Feb 21.

Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.

Robinson A, Kardos M, Kimball AB.

J Am Acad Dermatol. 2012 Mar;66(3):369-75. doi: 10.1016/j.jaad.2011.01.022. Epub 2011 Oct 29.

Disease impact & quality of life

Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

Psoriasis in Latin America and the Caribbean: A systematic review.

Hernández-Vásquez A, Molinari L, Larrea N, Ciapponi A.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1991-1998. doi: 10.1111/jdv.14393. Epub 2017 Jul 12.

Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013.

Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ, Langan SM, Nsoesie EO, Ferrari AJ, Erskine HE, Silverberg JI, Vos T, Naghavi M.

JAMA Dermatol. 2017 May 1;153(5):406-412. doi: 10.1001/jamadermatol.2016.5538.

Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis.

Shahwan KT, Kimball AB.

J Am Acad Dermatol. 2017 Jun;76(6):1198-1200.e1. doi: 10.1016/j.jaad.2017.02.002.

Health-related quality of life in children and adolescents with psoriasis: A systematic review and meta-analysis.

Randa H, Todberg T, Skov L, Larsen LS, Zachariae R.

Acta Derm Venereol. 2017 May 8;97(5):555-563. doi: 10.2340/00015555-2600.

Measuring the impact of dermatological conditions on family and caregivers: A review of dermatology-specific instruments.

Sampogna F, Finlay AY, Salek SS, Chernyshov P, Dalgard FJ, Evers AWM, Linder D, Manolache L, Marron SE, Poot F, Spillekom-van Koulik S, Svensson Å, Szepietowski JC, Tomas-Aragones L, Abeni D; European Academy of Dermatology and Venereology TaskForce on Quality of Life.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1429-1439. doi: 10.1111/jdv.14288. Epub 2017 May 19.

A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.

Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, Piguet V.

Br J Dermatol. 2017 Mar;176(3):577-593. doi: 10.1111/bjd.14788. Epub 2016 Oct 12.

Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: A systematic review and meta-analysis.

Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS.

J Eur Acad Dermatol Venereol. 2017 Feb;31(2):213-220. doi: 10.1111/jdv.14007. Epub 2016 Oct 28.

Systematic review of health-related quality of life in adolescents with psoriasis.

Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A.

Dermatology. 2016;232(5):541-549. doi: 10.1159/000450826. Epub 2016 Nov 4.

[Health-related quality of life in patients with psoriasis: A systematic review of the European literature.](#)

Obradors M, Blanch C, Comellas M, Figueras M, Lizan L.
Qual Life Res. 2016 Nov;25(11):2739-2754. Epub 2016 Jun 3.

[Quality of life impact of childhood skin conditions measured using the Children's Dermatology Life Quality Index \(CDLQI\): A meta-analysis.](#)

Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA.
Br J Dermatol. 2016 Apr;174(4):853-61. doi: 10.1111/bjd.14361. Epub 2016 Mar 6.

[EQ-5D in skin conditions: An assessment of validity and responsiveness.](#)

Yang Y, Brazier J, Longworth L.
Eur J Health Econ. 2015 Dec;16(9):927-39. doi: 10.1007/s10198-014-0638-9. Epub 2014 Oct 31.

[A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values.](#)

Møller AH, Erntoft S, Vinding GR, Jemec GB.
Patient Relat Outcome Meas. 2015 Jul 7;6:167-77. doi: 10.2147/PROM.S81428. eCollection 2015.

[Effect of the psoriasis on the health-related quality of life: Meta-analyses 2003-2013]

Cardona-Arias JA, Franco-Aguirre JQ.

Revista Argentina de Dermatología 2014;95(2). Spanish.

http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1851-300X2014000200002

[The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions.](#)

Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, Marks R, Naldi L, Weinstock MA, Wulf SK, Michaud C, J L Murray C, Naghavi M.
J Invest Dermatol. 2014 Jun;134(6):1527-34. doi: 10.1038/jid.2013.446. Epub 2013 Oct 28.

[Psoriasis Area Severity Index \(PASI\) and the Dermatology Life Quality Index \(DLQI\): The correlation between disease severity and psychological burden in patients treated with biological therapies.](#)

Mattei PL, Corey KC, Kimball AB.
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7. doi: 10.1111/jdv.12106. Epub 2013 Feb 21.

[Impact of TNF-α antagonists on the quality of life in selected skin diseases.](#)

Gisondi P, Girolomoni G.
G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

Economic burden

[The cost of psoriasis and psoriatic arthritis in 5 European countries: A systematic review.](#)

Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ.
Actas Dermosifiliogr. 2016 Sep;107(7):577-90. doi: 10.1016/j.ad.2016.04.018. Epub 2016 Jun 15.
English, Spanish.

[Economic burden of psoriasis in the United States: A systematic review.](#)

Brezinski EA, Dhillon JS, Armstrong AW.

JAMA Dermatol. 2015 Jun;151(6):651-8. doi: 10.1001/jamadermatol.2014.3593

Evaluating the economic burden of psoriasis in the United States.

Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, Lebwohl M.
J Am Acad Dermatol. 2015 Jun;72(6):961-7.e5. doi: 10.1016/j.jaad.2015.02.1099. Epub 2015 Apr 14.

The economic burden of psoriasis: A systematic literature review.

Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG.
Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):685-705. doi:
10.1586/14737167.2014.933671. Epub 2014 Jul 23.

Service delivery

Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review.

Cobo-Ibáñez T, Villaverde V, Seoane-Mato D, Muñoz-Fernández S, Guerra M, Del Campo PD, Cañete JD.
Rheumatol Int. 2016 Feb;36(2):221-9. doi: 10.1007/s00296-015-3377-z. Epub 2015 Oct 5.

Research methodology

Most systematic reviews of high methodological quality on psoriasis interventions are classified as high risk of bias using ROBIS tool.

Gómez-García F, Ruano J, Gay-Mimbrera J, Aguilar-Luque M, Sanz-Cabanillas JL, Alcalde-Mellado P, Maestre-López B, Carmona-Fernández PJ, González-Padilla M, García-Nieto AV, Isla-Tejera B.
J Clin Epidemiol. 2017 Dec;92:79-88. doi: 10.1016/j.jclinepi.2017.08.015. Epub 2017 Sep 9.

Author-paper affiliation network architecture influences the methodological quality of systematic reviews and meta-analyses of psoriasis.

Sanz-Cabanillas JL, Ruano J, Gomez-Garcia F, Alcalde-Mellado P, Gay-Mimbrera J, Aguilar-Luque M, Maestre-Lopez B, Gonzalez-Padilla M, Carmona-Fernandez PJ, Velez Garcia-Nieto A, Isla-Tejera B.
PLOS One. 2017 Apr 12;12(4):e0175419. doi: 10.1371/journal.pone.0175419. eCollection 2017.

Systematic reviews and meta-analyses on psoriasis: Role of funding sources, conflict of interest and bibliometric indices as predictors of methodological quality.

Gómez-García F, Ruano J, Aguilar-Luque M, Gay-Mimbrera J, Maestre-Lopez B, Sanz-Cabanillas JL, Carmona-Fernández PJ, González-Padilla M, Vélez García-Nieto A, Isla-Tejera B.
Br J Dermatol. 2017 Jun;176(6):1633-1644. doi: 10.1111/bjd.15380. Epub 2017 May 19.

Psoriasis registries worldwide: Systematic overview on registry publications.

Eissing L, Rustenbach SJ, Krensel M, Zander N, Spehr C, Radtke MA, Naldi L, Augustin M.
J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1100-6. doi: 10.1111/jdv.13634. Epub 2016 May 2

Placebo effects on itch: A meta-analysis of clinical trials of patients with dermatological conditions.

van Laarhoven AI, van der Sman-Mauriks IM, Donders AR, Pronk MC, van de Kerkhof PC, Evers AW.
J Invest Dermatol. 2015 May;135(5):1234-43. doi: 10.1038/jid.2014.522. Epub 2014 Dec 1.

Placebo response in relation to clinical trial design: A systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment.

Lamel SA, Myer KA, Younes N, Zhou JA, Maibach H, Maibach HI.
Arch Dermatol Res. 2012 Nov;304(9):707-17. doi: 10.1007/s00403-012-1266-9. Epub 2012 Jul 29.

[Physician Global Assessment \(PGA\) and Psoriasis Area and Severity Index \(PASI\): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.](#)

Robinson A, Kardos M, Kimball AB.
J Am Acad Dermatol. 2012 Mar;66(3):369-75. doi: 10.1016/j.jaad.2011.01.022. Epub 2011 Oct 29.

Paediatric psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

Use of topical therapies for pediatric psoriasis: A systematic review.

Kravas G, Gholam K.
Pediatr Dermatol. 2018 Mar 1. doi: 10.1111/pde.13422. [Epub ahead of print]

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.

Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.
Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.

Treatment of severe psoriasis in children: recommendations of an Italian expert group.

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.
Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

Health-related quality of life in children and adolescents with psoriasis: A systematic review and meta-analysis.

Randa H, Todberg T, Skov L, Larsen LS, Zachariae R.
Acta Derm Venereol. 2017 May 8;97(5):555-563. doi: 10.2340/00015555-2600.

The epidemiology of childhood psoriasis: A scoping review.

Burden-Teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R.
Br J Dermatol. 2016 Jun;174(6):1242-57. doi: 10.1111/bjd.14507. Epub 2016 May 22.

Systemic treatment of pediatric psoriasis: A review.

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

Systematic review of health-related quality of life in adolescents with psoriasis.

Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A.
Dermatology. 2016;232(5):541-549. doi: 10.1159/000450826. Epub 2016 Nov 4.

Quality of life impact of childhood skin conditions measured using the Children's Dermatology Life Quality Index (CDLQI): A meta-analysis.

Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA.
Br J Dermatol. 2016 Apr;174(4):853-61. doi: 10.1111/bjd.14361. Epub 2016 Mar 6.

Anti-tumor necrosis factor α-related psoriatic lesions in children with inflammatory bowel disease: Case report and systematic literature review.

Romiti R, Araujo KM, Steinwurz F, Denadai R.
Pediatr Dermatol. 2016 Mar-Apr;33(2):e174-8. doi: 10.1111/pde.12820.

Anti-TNF agents for paediatric psoriasis.

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.
Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2.

Systemic treatments in paediatric psoriasis: A systematic evidence-based update.

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

A systematic review of systemic medications for pustular psoriasis in pediatrics.

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.
Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

Psoriasis in difficult-to-treat sites

Nail psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

Reporting of outcomes in randomised controlled trials on nail psoriasis; a systematic review.
Busard CIM, Nolte JYC, Pasch MC, Spuls PI.
Br J Dermatol. 2017 Jul 19. doi: 10.1111/bjd.15831. [Epub ahead of print]

Splinter hemorrhages of the nails: A systematic review of clinical features and associated conditions.
Haber R, Khoury R, Kechichian E, Tomb R.
Int J Dermatol. 2016 Dec;55(12):1304-1310. doi: 10.1111/ijd.13347. Epub 2016 Jul 15.

Treatment of nail psoriasis: Best practice recommendations from the Medical Board of the National Psoriasis Foundation.
Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS; National Psoriasis Foundation.
JAMA Dermatol. 2015 Jan;151(1):87-94. doi: 10.1001/jamadermatol.2014.2983.

Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).
Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrández Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.
Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.
English, Spanish

Treatments for nail psoriasis: a systematic review by the GRAPPA Nail Psoriasis Work Group.
Armstrong AW, Tuong W, Love TJ, Carneiro S, Grysman R, Lee SS, Kavanaugh A.
J Rheumatol. 2014 Nov;41(11):2306-14. doi: 10.3899/jrheum.140881.

Interventions for nail psoriasis.

de Vries AC, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, Spuls PI.
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007633. doi: 10.1002/14651858.CD007633.pub2.

Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
Jemec GB, Ibler KS.
J Drugs Dermatol. 2012 Aug;11(8):939-42

Scalp psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

Topical treatments for scalp psoriasis: Summary of a Cochrane Systematic Review.

Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A.
Br J Dermatol. 2017 Mar;176(3):604-614. doi: 10.1111/bjd.14811. Epub 2016 Oct 19.

[Managing scalp psoriasis: An evidence-based review.](#)

Wang TS, Tsai TF.
Am J Clin Dermatol. 2017 Feb;18(1):17-43. doi: 10.1007/s40257-016-0222-4.

[Topical treatments for scalp psoriasis.](#)

Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A.
Cochrane Database Syst Rev. 2016 Feb 26;2:CD009687. doi: 10.1002/14651858.CD009687.pub2.

Scalp psoriasis: Systematic review comparing topical treatments and placebo.
Jales R, Hirata S, Attalah Á, Sá-Caputo D, Arnóbio A, Frederico É, Bernardo-Filho M, Saconato H.
Journal of Cosmetics, Dermatological Sciences and Applications 2015;5:142-150. doi:
10.4236/jcdsa.2015.52017.

http://file.scirp.org/pdf/JCDSA_2015062913403448.pdf

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF,
Carrascosa Carrillo JM, Ferrández Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-
Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E,
Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de
Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.
English, Spanish

[Topical treatments for chronic plaque psoriasis of the scalp: A systematic review.](#)

Mason AR, Mason JM, Cork MJ, Hancock H, Dooley G.
Br J Dermatol. 2013 Sep;169(3):519-27. doi: 10.1111/bjd.12393.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.
Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

Acral psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF,
Carrascosa Carrillo JM, Ferrández Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-
Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E,
Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de
Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.
English, Spanish

Flexural psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?](#)

Omland SH, Gniadecki R.

Clin Dermatol. 2015 Jul-Aug;33(4):456-61. doi: 10.1016/j.clindermatol.2015.04.007. Epub 2015 Apr 8.

Specific psoriasis phenotypes

Pustular psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: A systematic review.

Sanchez IM, Sorenson E, Levin E, Liao W.
Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.

What do we know about palmoplantar pustulosis?

Misiak-Galazka M, Wolska H, Rudnicka L.
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):38-44. doi: 10.1111/jdv.13846. Epub 2016 Aug 13.

Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion.

Sevrain M, Richard MA, Barnetche T, Rouzaud M, Villani AP, Paul C, Beylot-Barry M, Jullien D, Aractingi S, Aubin F, Joly P, Le Maitre M, Cantagrel A, Ortonne JP, Misery L.
J Eur Acad Dermatol Venereol. 2014 Aug;28 Suppl 5:13-6. doi: 10.1111/jdv.12561.

Interventions for chronic palmoplantar pustulosis.

Marsland AM, Chalmers RJ, Hollis S, Leonardi-Bee J, Griffiths CE.
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001433.

Guttate psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

Interventions for guttate psoriasis.

Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE.
Cochrane Database Syst Rev. 2000;(2):CD001213.

Antistreptococcal interventions for guttate and chronic plaque psoriasis.

Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE.
Cochrane Database Syst Rev. 2000;(2):CD001976.

Therapies in general

Therapies in general – economic evaluation

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.
Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

[Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.
PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Health economic analyses of psoriasis management: A systematic literature search.](#)

Gutknecht M, Krensel M, Augustin M.
Arch Dermatol Res. 2016 Nov;308(9):601-616. Epub 2016 Jul 19.

[Systematic review of cost-effectiveness analyses of treatments for psoriasis.](#)

Zhang W, Islam N, Ma C, Anis AH.
Pharmacoeconomics. 2015 Apr;33(4):327-40. doi: 10.1007/s40273-014-0244-9.

[Psoriasis treatment and management - A systematic review of full economic evaluations.](#)

Hamilton MP, Ntais D, Griffiths CE, Davies LM; Identification and Management of Psoriasis-Associated ComorbidiTy (IMPACT) Team..
Br J Dermatol. 2015 Mar;172(3):574-83. doi: 10.1111/bjd.13486. Epub 2015 Feb 11.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.
J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.](#)

Wang SH, Chi CC, Hu S.
Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

[Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: A systematic review of published models and clinical practice guidelines.](#)

Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR.
Pharmacoeconomics. 2014 Apr;32(4):395-409. doi: 10.1007/s40273-014-0130-5.

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.
Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.](#)

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P. Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

Therapies in general – patient preferences

[Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.](#)

Florek AG, Wang CJ, Armstrong AW. Arch Dermatol Res. 2018 Feb 13. doi: 10.1007/s00403-018-1808-x. [Epub ahead of print]

[Evaluating risk tolerance from a systematic review of preferences: The case of patients with psoriasis.](#)

Gonzalez JM. Patient. 2018 Jan 13. doi: 10.1007/s40271-017-0295-z. [Epub ahead of print]

[Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: A systematic review of the literature.](#)

Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Patient Prefer Adherence. 2016 Nov 17;10:2357-2367. eCollection 2016.

[A systematic review on methods used to evaluate patient preferences in psoriasis treatments.](#)

Gutknecht M, Schaarschmidt ML, Herrlein O, Augustin M. J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1454-64. doi: 10.1111/jdv.13749. Epub 2016 Jul 19.

[Elicitation and use of patients' preferences in the treatment of psoriasis: A systematic review.](#)

Umar N, Yamamoto S, Loerbroks A, Terris D. Acta Derm Venereol. 2012 Jul;92(4):341-6. doi: 10.2340/00015555-1304.

Therapies in general – adherence

[eHealth technologies as an intervention to improve adherence to topical antipsoriatics: A systematic review.](#)

Svendsen MT, Andersen F, Andersen KE. J Dermatolog Treat. 2018 Mar;29(2):123-128. doi: 10.1080/09546634.2017.1341612. Epub 2017 Jun 29.

[Medical adherence to topical corticosteroid preparations prescribed for psoriasis: A systematic review.](#)

Svendsen MT, Andersen F, Hansen J, Johannessen H, Andersen KE. J Dermatolog Treat. 2017 Feb;28(1):32-39. doi: 10.1080/09546634.2016.1178375. Epub 2016 May 6.

[Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: A systematic review of the literature.](#)

Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Patient Prefer Adherence. 2016 Nov 17;10:2357-2367. eCollection 2016.

[Methodologies for medication adherence evaluation: Focus on psoriasis topical treatment.](#)

Teixeira A, Teixeira M, Almeida V, Torres T, Sousa Lobo JM, Almeida IF.

J Dermatol Sci. 2016 May;82(2):63-8. doi: 10.1016/j.jdermsci.2016.02.008. Epub 2016 Feb 18.

Interventions to improve adherence in patients with immune-mediated inflammatory disorders: A systematic review.

Depont F, Berenbaum F, Filippi J, Le Maitre M, Nataf H, Paul C, Peyrin-Biroulet L, Thibout E. PLoS One. 2015 Dec 16;10(12):e0145076. doi: 10.1371/journal.pone.0145076. eCollection 2015.

A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases.

Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J.

Adv Ther. 2015 Nov;32(11):983-1028. doi: 10.1007/s12325-015-0256-7. Epub 2015 Nov 7.

Does mHealth increase adherence to medication? Results of a systematic review.

Anglada-Martinez H, Riu-Viladoms G, Martin-Conde M, Rovira-Illamola M, Sotoca-Momblona JM, Codina-Jane C.

Int J Clin Pract. 2015 Jan;69(1):9-32. doi: 10.1111/ijcp.12582. Epub 2014 Dec 4.

Adherence to medication in patients with psoriasis: A systematic literature review.

Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L.

Br J Dermatol. 2013 Jan;168(1):20-31. doi: 10.1111/bjd.12039.

Adherence to topical treatment in psoriasis: A systematic literature review.

Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, Aractingi S, Aubin F, Bachelez H, Cribier B, Jullien D, Le Maître M, Richard MA, Ortonne JP, Paul C.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:61-7. doi: 10.1111/j.1468-3083.2012.04525.x.

Topical treatments

Topical treatments - general

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.
Pediatr Dermatol. 2018 Mar 1. doi: 10.1111/pde.13422. [Epub ahead of print]

[eHealth technologies as an intervention to improve adherence to topical antipsoriatics: A systematic review.](#)

Svendsen MT, Andersen F, Andersen KE.
J Dermatolog Treat. 2018 Mar;29(2):123-128. doi: 10.1080/09546634.2017.1341612. Epub 2017 Jun 29.

[Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.](#)

Koo K, Jeon C, Bhutani T.
J Dermatolog Treat. 2017 Dec;28(8):702-708. doi: 10.1080/09546634.2017.1328098. Epub 2017 Jun 6.

[Worldwide utilization of topical remedies in treatment of psoriasis: A systematic review.](#)

Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H.
J Dermatolog Treat. 2017 Aug;28(5):374-383. doi: 10.1080/09546634.2016.1254331. Epub 2016 Nov 13.

[Comparative effectiveness of topical drugs in dermatologic priority diseases: Geometry of randomized trial networks.](#)

Maruani A, Samimi M, Lorette G, le Cleach L.
J Invest Dermatol. 2015 Jan;135(1):76-83. doi: 10.1038/jid.2014.296. Epub 2014 Jun 21.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.
J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.
Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical combination treatments

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.

Koo K, Jeon C, Bhutani T.

J Dermatolog Treat. 2017 Dec;28(8):702-708. doi: 10.1080/09546634.2017.1328098. Epub 2017 Jun 6.

Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.

Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, Thaci D.

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22.

Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review.

Yan R, Jiang S, Wu Y, Gao XH, Chen HD.

Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):135-44. doi: 10.4103/0378-6323.175919.

Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: Position paper on evidence and use in daily practice.

Augustin M, Mrowietz U, Bonnekoh B, Rosenbach T, Thaci D, Reusch M, Arbabili M, Reich K.

J Dtsch Dermatol Ges. 2014 Aug;12(8):667-82. doi: 10.1111/ddg.12396. Epub 2014 Jul 17.

Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.

Mason A, Mason J, Cork M, Hancock H, Dooley G.

J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: A systematic literature review.

Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC.

J Eur Acad Dermatol Venereol. 2013 Aug;27(8):931-51. doi: 10.1111/jdv.12058. Epub 2012 Dec 20.

Combinations of classical time-honoured topicals in plaque psoriasis: A systematic review.

Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC.

J Eur Acad Dermatol Venereol. 2013 Apr;27(4):399-410. doi: 10.1111/j.1468-3083.2012.04640.x.

Epub 2012 Jul 11.

Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.

Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

Topical treatments for chronic plaque psoriasis.

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical corticosteroids

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gharam K.

Pediatr Dermatol. 2018 Mar 1. doi: 10.1111/pde.13422. [Epub ahead of print]

[Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.](#)

Iversen L, Dauden E, Segal S, Freeman K, Magina S, Rigopoulos D, Thaci D.

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22.

[Medical adherence to topical corticosteroid preparations prescribed for psoriasis: A systematic review.](#)

Svendsen MT, Andersen F, Hansen J, Johannessen H, Andersen KE.

J Dermatolog Treat. 2017 Feb;28(1):32-39. doi: 10.1080/09546634.2016.1178375. Epub 2016 May 6.

[Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: Position paper on evidence and use in daily practice.](#)

Augustin M, Mrowietz U, Bonnekoh B, Rosenbach T, Thaci D, Reusch M, Ardabili M, Reich K.

J Dtsch Dermatol Ges. 2014 Aug;12(8):667-82. doi: 10.1111/ddg.12396. Epub 2014 Jul 17.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.

J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.

Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

[Topical corticosteroids in plaque psoriasis: A systematic review of efficacy and treatment modalities.](#)

Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, Jullien D, Aubin F, Bachelez H, Joly P, Le Maître M, Misery L, Richard MA, Paul C, Ortonne JP.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:36-46. doi: 10.1111/j.1468-3083.2012.04522.x.

[Topical corticosteroids in plaque psoriasis: A systematic review of risk of adrenal axis suppression and skin atrophy.](#)

Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, Jullien D, Aubin F, Bachelez H, Joly P, Le Maître M, Misery L, Richard MA, Paul C, Ortonne JP.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:47-51. doi: 10.1111/j.1468-3083.2012.04523.x.

Topical vitamin D analogues

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.

Pediatr Dermatol. 2018 Mar 1. doi: 10.1111/pde.13422. [Epub ahead of print]

[Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.](#)

Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, Thaci D.

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22.

[Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: Position paper on evidence and use in daily practice.](#)

Augustin M, Mrowietz U, Bonnekoh B, Rosenbach T, Thaci D, Reusch M, Ardabili M, Reich K.

J Dtsch Dermatol Ges. 2014 Aug;12(8):667-82. doi: 10.1111/ddg.12396. Epub 2014 Jul 17.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.

J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.

Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

[Topical vitamin D analogues alone or in association with topical steroids for psoriasis: A systematic review.](#)

Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, Aractingi S, Aubin F, Bachelez H, Cribier B, Jullien D, Le Maître M, Richard MA, Ortonne JP, Paul C.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:S2-60. doi: 10.1111/j.1468-3083.2012.04524.x.

Topical dithranol

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.

Pediatr Dermatol. 2018 Mar 1. doi: 10.1111/pde.13422. [Epub ahead of print]

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.

J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.

Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

Topical treatments for chronic plaque psoriasis.

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical retinoids

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.

Mason A, Mason J, Cork M, Hancock H, Dooley G.

J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.

Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

Topical treatments for chronic plaque psoriasis.

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical coal tar

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.

Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

Topical treatments for chronic plaque psoriasis.

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Emollients and keratolytics

Keratolytics and emollients and their role in the therapy of psoriasis: A systematic review.

Jacobi A, Mayer A, Augustin M.

Dermatol Ther (Heidelb). 2015 Mar;5(1):1-18. doi: 10.1007/s13555-015-0068-3. Epub 2015 Jan 21.

Topical treatments for chronic plaque psoriasis.

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical urea

[Urea: a comprehensive review of the clinical literature.](#)

Pan M, Heinecke G, Bernardo S, Tsui C, Levitt J.
Dermatol Online J. 2013 Nov 15;19(11):20392.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Other topical treatments

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gharam K.
Pediatr Dermatol. 2018 Mar 1. doi: 10.1111/pde.13422. [Epub ahead of print]

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Phototherapy

Phototherapy

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.

Théréné C, Brenaut E, Barnetche T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

Treatment of severe psoriasis in children: recommendations of an Italian expert group.

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.
Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

A systematic review of light emitting diode (LED) phototherapy for treatment of psoriasis: An emerging therapeutic modality.

Ho D, Koo E, Mamalis A, Jagdeo J.
J Drugs Dermatol. 2017 May 1;16(5):482-488.

Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.

Koo K, Jeon C, Bhutani T.
J Dermatolog Treat. 2017 Dec;28(8):702-708. doi: 10.1080/09546634.2017.1328098. Epub 2017 Jun 6.

Systemic treatment of pediatric psoriasis: A review.

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

Improving access to home phototherapy for patients with psoriasis: current challenges and future prospects.

Franken SM, Vierstra CL, Rustemeyer T.
Psoriasis (Auckl). 2016 May 18;6:55-64. doi: 10.2147/PTT.S81958. eCollection 2016.

Effects of narrow band ultraviolet B on serum levels of vascular endothelial growth factor and interleukin-8 in patients with psoriasis.

Chen HQ, Li X, Tang R.
Am J Ther. 2016 May-Jun;23(3):e655-62. doi: 10.1097/MJT.0000000000000330.

Targeted phototherapy.

Mysore V, Shashikumar BM.
Indian J Dermatol Venereol Leprol. 2016 Jan-Feb;82(1):1-6. doi: 10.4103/0378-6323.172902.

Photodynamic therapy for psoriasis.

Choi YM, Adelzadeh L, Wu JJ.
J Dermatolog Treat. 2015 Jun;26(3):202-7. doi: 10.3109/09546634.2014.927816. Epub 2014 Jun 17.

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

Efficacy of localized phototherapy and photodynamic therapy for psoriasis: A systematic review and meta-analysis.

Almutawa F, Thalib L, Hekman D, Sun Q, Hamzavi I, Lim HW.

Photodermat Photoimmunol Photomed. 2015 Jan;31(1):5-14. doi: 10.1111/phpp.12092. Epub 2013 Dec 20.

Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis.

Chen X, Yang M, Cheng Y, Liu GJ, Zhang M.

Cochrane Database Syst Rev. 2013 Oct 23;(10):CD009481. doi: 10.1002/14651858.CD009481.pub2

Systematic review of UV-based therapy for psoriasis.

Almutawa F, Alnomair N, Wang Y, Hamzavi I, Lim HW.

Am J Clin Dermatol. 2013 Apr;14(2):87-109. doi: 10.1007/s40257-013-0015-y.

Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review.

Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:22-31. doi: 10.1111/j.1468-3083.2012.04520.x.

Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review.

Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:11-21. doi: 10.1111/j.1468-3083.2012.04519.x.

Guidelines for bath PUVA, bathing suit PUVA and soak PUVA.

Pai SB, Shetty S.

Indian J Dermatol Venereol Leprol. 2015 Nov-Dec;81(6):559-67. doi: 10.4103/0378-6323.168336.

A review of targeted ultraviolet B phototherapy for psoriasis.

Mudigonda T, Dabade TS, Feldman SR.

J Am Acad Dermatol. 2012 Apr;66(4):664-72. doi: 10.1016/j.jaad.2011.07.011. Epub 2011 Oct 14.

Laser therapy

308nm excimer laser in dermatology.

Mehrabian S, Feily A.

J Lasers Med Sci. 2014 Winter;5(1):8-12.

The efficacy of pulsed dye laser treatment for inflammatory skin diseases: A systematic review.

Ercég A, de Jong EM, van de Kerkhof PC, Seyger MM.

J Am Acad Dermatol. 2013 Oct;69(4):609-615.e8. doi: 10.1016/j.jaad.2013.03.029. Epub 2013 May 24

Systemic treatments in general

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.
Cutis. 2018 Jan;101(1):38;42;56.

[Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.](#)

Florek AG, Wang CJ, Armstrong AW.
Arch Dermatol Res. 2018 Feb 13. doi: 10.1007/s00403-018-1808-x. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.
Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.
Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: A systematic review.

Boehncke WH, Alvarez Martinez D, Solomon JA, Gottlieb AB.
J Rheumatol. 2014 Nov;41(11):2301-5. doi: 10.3899/jrheum.140880.

Network meta-analysis of treatments for chronic plaque psoriasis in Canada.

Gupta AK, Daigle D, Lyons DC.
J Cutan Med Surg. 2014 Nov;18(6):371-8.

Combined use of systemic agents for psoriasis: A systematic review.

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.
JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

A systematic review of systemic medications for pustular psoriasis in pediatrics.

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.
Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.
Curr Pharm Des. 2014;20(4):500-12.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.
Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.
J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.
J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x.
Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.

Wong JW, Koo JY.

Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Conventional (non-biologic) systemic therapies

Methotrexate

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

Treatment of severe psoriasis in children: recommendations of an Italian expert group.

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: A systematic review and meta-analysis of randomized, placebo-controlled trials.

Mazaud C, Fardet L.

Br J Dermatol. 2017 Oct;177(4):978-986. doi: 10.1111/bjd.15377. Epub 2017 Aug 30.

Systemic treatment of pediatric psoriasis: A review.

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials.

West J, Ogston S, Foerster J.

PLoS One. 2016 May 11;11(5):e0153740. doi: 10.1371/journal.pone.0153740. eCollection 2016.
Erratum in: PLoS One. 2016;11(7):e0158928.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Methotrexate in moderate to severe psoriasis: Review of the literature and expert recommendations.](#)

Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G, Ferrández L, Sánchez-Carazo JL, Daudén E, López-Estebaranz JL, Vidal D, Herranz P, Jorquera E, Coto-Segura P, Ribera M.
Actas Dermosifiliogr. 2016 Apr;107(3):194-206. doi: 10.1016/j.ad.2015.10.005. Epub 2015 Nov 21.
English, Spanish.

[Methotrexate dosing regimen for plaque-type psoriasis: A systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation.](#)

Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI.
Acta Derm Venereol. 2016 Jan;96(1):23-8. doi: 10.2340/00015555-2081.

[Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: Novel therapeutic insights coming from a meta-analysis of the literature data.](#)

De Vecchis R, Baldi C, Palmisani L.
Anatol J Cardiol. 2016 Jan;16(1):2-9. doi: 10.5152/akd.2015.6136.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials.](#)

Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ.
Semin Arthritis Rheum. 2015 Oct;45(2):156-62. doi: 10.1016/j.semarthrit.2015.05.003. Epub 2015 May 19.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepi MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.
Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

Systemic treatments in paediatric psoriasis: A systematic evidence-based update.

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: Systematic literature review and meta-analysis of randomised controlled trials.

Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ.
BMJ. 2015 Mar 13;350:h1269. doi: 10.1136/bmj.h1269.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.
Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

Network meta-analysis of treatments for chronic plaque psoriasis in Canada.

Gupta AK, Daigle D, Lyons DC.
J Cutan Med Surg. 2014 Nov;18(6):371-8.

Combined use of systemic agents for psoriasis: A systematic review.

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.
JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.
Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

Methotrexate and liver fibrosis in people with psoriasis: A systematic review of observational studies.

Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH.
Br J Dermatol. 2014 Jul;171(1):17-29. doi: 10.1111/bjd.12941. Epub 2014 Jul 15.

A systematic review of systemic medications for pustular psoriasis in pediatrics.

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.
Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: A systematic review and meta-analysis.

Maybury CM, Samarasekera E, Douiri A, Barker JN, Smith CH.
Br J Dermatol. 2014 Jun;170(6):1237-47. doi: 10.1111/bjd.12905.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.
Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

Ciclosporin

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

Systemic treatment of pediatric psoriasis: A review.

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.

Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

Systematic review on the maintenance of response during systemic antipsoriatic therapy.

Jacobs A, Rosumeck S, Nast A.

Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

Systemic treatments in paediatric psoriasis: A systematic evidence-based update.

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Combined use of systemic agents for psoriasis: A systematic review.

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.

JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

A systematic review of systemic medications for pustular psoriasis in pediatrics.

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.

Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

Ciclosporin use during pregnancy.

Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, Coscia L, Armenti V.

Drug Saf. 2013 May;36(5):279-94. doi: 10.1007/s40264-013-0034-x.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)

Wong JW, Koo JY.
Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Systemic retinoids

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.
Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.
Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

Systemic treatments in paediatric psoriasis: A systematic evidence-based update.

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

A systematic review of systemic medications for pustular psoriasis in pediatrics.

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.

Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

Colchicine

Systemic treatments in paediatric psoriasis: A systematic evidence-based update.

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Fumaric acid esters

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.

Balak DMW, Hajdarbegovic E, Brammer WM, Neumann HAM, Thio HB.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1475-1482. doi: 10.1111/jdv.14236. Epub 2017 Apr 25.

Fumaric acid esters for psoriasis: A systematic review.

Smith D.

Ir J Med Sci. 2017 Feb;186(1):161-177. doi: 10.1007/s11845-016-1470-2. Epub 2016 Jun 7.

Oral fumaric acid esters for psoriasis: Abridged Cochrane systematic review including GRADE assessments.

Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V.

Br J Dermatol. 2016 Nov;175(5):873-881. doi: 10.1111/bjd.14676. Epub 2016 Aug 29.

Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: A systematic review of randomized and observational studies.

Balak DM, Fallah Arani S, Hajdarbegovic E, Hagemans CA, Bramer WM, Thio HB, Neumann HA.

Br J Dermatol. 2016 Aug;175(2):250-62. doi: 10.1111/bjd.14500. Epub 2016 Jul 19.

Systemic treatment of pediatric psoriasis: A review.

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.

Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

Systematic review on the maintenance of response during systemic antipsoriatic therapy.

Jacobs A, Rosumeck S, Nast A.

Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

Oral fumaric acid esters for psoriasis.

Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V.

Cochrane Database Syst Rev. 2015 Aug 10;(8):CD010497. doi: 10.1002/14651858.CD010497.pub2.

Systemic treatments in paediatric psoriasis: A systematic evidence-based update.

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

Antibiotics

Systemic treatments in paediatric psoriasis: A systematic evidence-based update.

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Antistreptococcal interventions for guttate and chronic plaque psoriasis.

Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE.

Cochrane Database Syst Rev. 2000;(2):CD001976.

Thiazolidinediones

Thiazolidinediones for plaque psoriasis: A systematic review and meta-analysis.

Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S.

Evid Based Med. 2012 Dec;17(6):171-6. doi: 10.1136/ebmed-2011-100388. Epub 2012 Apr 20.

Statins

The effect of statins on severity of psoriasis: A systematic review.

Ramessur R, Gill D.

Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):154-161. doi: 10.4103/0378-6323.188655.

Lactoferrin

A systematic review of lactoferrin use in dermatology.

Hassoun LA, Sivamani RK.

Crit Rev Food Sci Nutr. 2017 Nov 22;57(17):3632-3639. doi: 10.1080/10408398.2015.1137859.

Omega-3 fatty acids

Effect of omega-3 fatty acids on disease severity in patients with psoriasis: A systematic review.

Upala S, Yong WC, Theparee T, Sanguankeo A.

Int J Rheum Dis. 2017 Apr;20(4):442-450. doi: 10.1111/1756-185X.13051. Epub 2017 Mar 5.

Diet and psoriasis, part III: Role of nutritional supplements.

Millsop JW, Bhatia BK, Debbaneh M, Koo J, Liao W.

J Am Acad Dermatol. 2014 Sep;71(3):561-9. doi: 10.1016/j.jaad.2014.03.016. Epub 2014 Apr 26.

Systemic biologic therapies

Biologics & small molecule inhibitors in general – efficacy & safety

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.

[Epub ahead of print]

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.

Florek AG, Wang CJ, Armstrong AW.

Arch Dermatol Res. 2018 Feb 13. doi: 10.1007/s00403-018-1808-x. [Epub ahead of print]

Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: A systematic review.

Sanchez IM, Sorenson E, Levin E, Liao W.

Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.

A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

Drug survival of biologic treatments in psoriasis: a systematic review.

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2017 Oct 27:1-28. doi: 10.1080/09546634.2017.1398393. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Exposure to biologic therapies during conception and pregnancy: A systematic review.](#)

Pottinger EM, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH.

Br J Dermatol. 2018 Jan;178(1):95-102. doi: 10.1111/bjd.15802. Epub 2017 Dec 14.

[Risk of cancer in patients with psoriasis on biologic therapies: A systematic review.](#)

Peleva E, Exton LS, Kelley K, Mason KJ, Smith CH.

Br J Dermatol. 2018 Jan;178(1):103-113. doi: 10.1111/bjd.15830. Epub 2017 Dec 18.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.

Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals.](#)

Fink DL, Hedley L, Miller RF.

Int J STD AIDS. 2017 Feb;28(2):110-119. doi: 10.1177/0956462416675109. Epub 2016 Oct 13.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.

Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepiti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.

Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.

Sorenson E, Koo J.

J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrández Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.

English, Spanish

Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.

Puig L, López A, Vilarrasa E, García I.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: A systematic review.

Boehncke WH, Alvarez Martinez D, Solomon JA, Gottlieb AB.

J Rheumatol. 2014 Nov;41(11):2301-5. doi: 10.3899/jrheum.140880.

Network meta-analysis of treatments for chronic plaque psoriasis in Canada.

Gupta AK, Daigle D, Lyons DC.

J Cutan Med Surg. 2014 Nov;18(6):371-8.

Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.

Wang SH, Chi CC, Hu S.

Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.

Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.

Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.

Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x. Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

[Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.](#)

Jemec GB, Ibler KS.

J Drugs Dermatol. 2012 Aug;11(8):939-42

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)

Wong JW, Koo JY.

Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

[Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.](#)

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Biologics – immunogenicity, treatment failure & treatment regimens

Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

Review of maintenance of response to psoriasis treatments.

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: A systematic review of published models and clinical practice guidelines.

Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR.

Pharmacoeconomics. 2014 Apr;32(4):395-409. doi: 10.1007/s40273-014-0130-5.

Antidrug antibodies in psoriasis: A systematic review.

Hsu L, Snodgrass BT, Armstrong AW.

Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: Systematic review and meta-analysis.

Maneiro JR, Salgado E, Gomez-Reino JJ.

JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.

Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.

Brezinski EA, Armstrong AW.

PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

Biologics – risk of infections

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.

Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L.

J Am Acad Dermatol. 2017 Jul;77(1):88-97.e5. doi: 10.1016/j.jaad.2017.01.037. Epub 2017 May 9.

Risk of tuberculosis in patients treated with TNF- α antagonists: A systematic review and meta-analysis of randomised controlled trials.

Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, Yu M.

BMJ Open. 2017 Mar 22;7(3):e012567. doi: 10.1136/bmjopen-2016-012567.

Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: A systematic review and meta-analysis.

Marra F, Lo E, Kalashnikov V, Richardson K.
Open Forum Infect Dis. 2016 Sep 28;3(4):ofw205. eCollection 2016 Oct.

Risk of serious infections in patients with psoriasis on biologic therapies: A systematic review and meta-analysis.

Yiu ZZ, Exton LS, Jabbar-Lopez Z, Mohd Mustapa MF, Samarasekera EJ, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Ashcroft DM, Griffiths CE, Smith CH, Warren RB.
J Invest Dermatol. 2016 Aug;136(8):1584-91. doi: 10.1016/j.jid.2016.03.035. Epub 2016 Apr 13.

Comparative risk of harm associated with the use of targeted immunomodulators: A systematic review.

Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, Mazinanian A, Glechner A, Gopalakrishnan C, Hansen RA.
Arthritis Care Res (Hoboken). 2016 Aug;68(8):1078-88. doi: 10.1002/acr.22815.

To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.

Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW.
J Am Acad Dermatol. 2015 Sep;73(3):420-8.e1. doi: 10.1016/j.jaad.2015.06.004. Epub 2015 Jul 14.

Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.

Sorenson E, Koo J.
J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.
Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.
Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: A systematic review and meta-analysis of randomized controlled trials and long-term extension studies.

Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ.
Rheumatology (Oxford). 2014 Oct;53(10):1872-85. doi: 10.1093/rheumatology/keu172. Epub 2014 May 11.

The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.

Wong JW, Koo JY.
Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Biologics – effect on co-morbidities

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals.](#)

Fink DL, Hedley L, Miller RF.

Int J STD AIDS. 2017 Feb;28(2):110-119. doi: 10.1177/0956462416675109. Epub 2016 Oct 13.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.

Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis.](#)

Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN.

Gastroenterology. 2016 Jul;151(1):97-109.e4. doi: 10.1053/j.gastro.2016.03.037. Epub 2016 Apr 1.

[Tumour necrosis factor- \$\alpha\$ inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety.](#)

Abbott R, Whear R, Nikolaou V, Bethel A, Coon JT, Stein K, Dickens C.

J Psychosom Res. 2015 Sep;79(3):175-84. doi: 10.1016/j.jpsychores.2015.04.008. Epub 2015 Apr 23.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.

J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.](#)

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.
Curr Pharm Des. 2014;20(4):500-12.

An evidence-based review of skin cancer rates on biologic therapies.
Kamangar F, Neuhaus IM, Koo JY.
J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.
Wong JW, Koo JY.
Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Biosimilars

How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials.
Wan MT, Strober BE, Wu JJ, Shin DB, Gelfand JM.
J Am Acad Dermatol. 2017 Sep;77(3):569-572. doi: 10.1016/j.jaad.2017.05.032. No abstract available.

Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.
Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.
BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

Biosimilars for the treatment of chronic inflammatory diseases: A systematic review of published evidence.
Jacobs I, Petersel D, Isakov L, Lula S, Lea Sewell K.
BioDrugs. 2016 Dec;30(6):525-570.

Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.
Nast A, Rosumeck S, Seidenschnur K.
J Dtsch Dermatol Ges. 2015 Apr;13(4):294-300. doi: 10.1111/ddg.12621. Review.

Anti-TNF agents

Anti-TNF agents - general

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis.
Juan S, Jiabi Z.
Joint Bone Spine. 2018 Apr 7. pii: S1297-319X(18)30050-2. doi: 10.1016/j.jbspin.2018.03.007. [Epub ahead of print]

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.
Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

[\[EXPRESS\] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.
Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.
J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.
[Epub ahead of print]

[Biologics and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.
PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.
Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: A systematic review.](#)

Sanchez IM, Sorenson E, Levin E, Liao W.
Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.
J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.
J Dermatolog Treat. 2017 Oct 27:1-28. doi: 10.1080/09546634.2017.1398393. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Exposure to biologic therapies during conception and pregnancy: A systematic review.](#)

Pottinger EM, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH.
Br J Dermatol. 2018 Jan;178(1):95-102. doi: 10.1111/bjd.15802. Epub 2017 Dec 14.

[Risk of cancer in patients with psoriasis on biologic therapies: A systematic review.](#)

Peleva E, Exton LS, Kelley K, Mason KJ, Smith CH.
Br J Dermatol. 2018 Jan;178(1):103-113. doi: 10.1111/bjd.15830. Epub 2017 Dec 18.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.
Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.
Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Risk of tuberculosis in patients treated with TNF- \$\alpha\$ antagonists: A systematic review and meta-analysis of randomised controlled trials.](#)

Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, Yu M.
BMJ Open. 2017 Mar 22;7(3):e012567. doi: 10.1136/bmjopen-2016-012567.

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.
Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Systematic review of efficacy of anti-tumor necrosis factor \(TNF\) therapy in patients with psoriasis previously treated with a different anti-TNF agent.](#)

Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC.
J Am Acad Dermatol. 2016 Sep;75(3):612-618.e6. doi: 10.1016/j.jaad.2016.02.1221. Epub 2016 Apr 6.

[Comparative risk of harm associated with the use of targeted immunomodulators: A systematic review.](#)

Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, Mazinanian A, Glechner A, Gopalakrishnan C, Hansen RA.
Arthritis Care Res (Hoboken). 2016 Aug;68(8):1078-88. doi: 10.1002/acr.22815.

[Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: A meta-analysis.](#)

Lee YH, Choi SJ, Ji JD, Song GG.
Pharmacogenomics. 2016 Aug;17(13):1465-77. doi: 10.2217/pgs.16.27. Epub 2016 Aug 4.

[Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis.](#)

Shelton E, Laharie D, Scott FI, Mamani R, Lewis JD, Colombel JF, Ananthakrishnan AN.
Gastroenterology. 2016 Jul;151(1):97-109.e4. doi: 10.1053/j.gastro.2016.03.037. Epub 2016 Apr 1.

[Malignancy risk of anti-tumor necrosis factor alpha blockers: An overview of systematic reviews and meta-analyses.](#)

Chen Y, Sun J, Yang Y, Huang Y, Liu G.
Clin Rheumatol. 2016 Jan;35(1):1-18. doi: 10.1007/s10067-015-3115-7. Epub 2015 Nov 16.

Anti-TNF agents for paediatric psoriasis.

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.
Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2.

The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis.

Chen W, Xu H, Wang X, Gu J, Xiong H, Shi Y.
Int Immunopharmacol. 2015 Sep;28(1):146-53. doi: 10.1016/j.intimp.2015.05.049. Epub 2015 Jun 9.

Tumour necrosis factor- α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety.

Abbott R, Whear R, Nikolaou V, Bethel A, Coon JT, Stein K, Dickens C.
J Psychosom Res. 2015 Sep;79(3):175-84. doi: 10.1016/j.jpsychores.2015.04.008. Epub 2015 Apr 23.

Association between TNF- α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF- α blockers in spondyloarthropathy, psoriasis and Crohn's disease: A meta-analysis.

Song GG, Seo YH, Kim JH, Choi SJ, Ji JD, Lee YH.
Pharmacogenomics. 2015;16(12):1427-37. doi: 10.2217/pgs.15.90. Epub 2015 Aug 5.

Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.

Gilbert KE, Manalo IF, Wu JJ.
J Am Acad Dermatol. 2015 Aug;73(2):329-31. doi: 10.1016/j.jaad.2015.04.012.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.
Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.
Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: A systematic review.

Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW.
Curr Pharm Des. 2014;20(4):513-28.

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.

Garcés S, Demengeot J, Benito-Garcia E.
Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: Systematic review and meta-analysis.

Maneiro JR, Salgado E, Gomez-Reino JJ.
JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.

[Impact of TNF- \$\alpha\$ antagonists on the quality of life in selected skin diseases.](#)
Gisondi P, Girolomoni G.
G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)
Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.
J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Treatment of nail psoriasis with TNF- \$\alpha\$ or IL12/23 inhibitors.](#)
Jemec GB, Ibler KS.
J Drugs Dermatol. 2012 Aug;11(8):939-42

[Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.](#)
Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.
Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)
Wong JW, Koo JY.
Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Anti-TNF agents – induced psoriasis

[Tumor necrosis factor- \$\alpha\$ inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience.](#)
Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, Linos E, Liao W, Haemel A.
J Am Acad Dermatol. 2017 Feb;76(2):334-341. doi: 10.1016/j.jaad.2016.08.012. Epub 2016 Oct 5.

[Paradoxical reactions induced by tumor necrosis factor-alpha antagonists: A literature review based on 46 cases.](#)
Olteanu R, Zota A.
Indian J Dermatol Venereol Leprol. 2016 Jan-Feb;82(1):7-12. doi: 10.4103/0378-6323.172898.

[Induction or exacerbation of psoriatic lesions during anti-TNF- \$\alpha\$ therapy for inflammatory bowel disease: A systematic literature review based on 222 cases.](#)
Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R.
J Crohns Colitis. 2013 Aug;7(7):517-24. doi: 10.1016/j.crohns.2012.08.007. Epub 2012 Sep 7.

[The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: Should biological therapy be suspended?](#)
Denadai R, Teixeira FV, Saad-Hossne R.
Arq Gastroenterol. 2012 Apr-Jun;49(2):172-6

Anti-TNF agents - etanercept

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: Systematic review of the literature and meta-analysis.

Carrascosa JM, Rebollo F, Gómez S, de la Cueva P.

J Dermatolog Treat. 2018 Apr 19:1-20. doi: 10.1080/09546634.2018.1467536. [Epub ahead of print]

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.

[Epub ahead of print]

Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.

Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.

Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.

Drug survival of biologic treatments in psoriasis: a systematic review.

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2017 Oct 27:1-28. doi: 10.1080/09546634.2017.1398393. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.

Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.

Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Anti-TNF agents for paediatric psoriasis.](#)

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.
Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.](#)

Gilbert KE, Manalo IF, Wu JJ.
J Am Acad Dermatol. 2015 Aug;73(2):329-31. doi: 10.1016/j.jaad.2015.04.012.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepi MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.
Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.
J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.

Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.](#)

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Piernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrández Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.

English, Spanish

[Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.](#)

Puig L, López A, Vilarrasa E, García I.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.

J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Combined use of systemic agents for psoriasis: A systematic review.](#)

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.

JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

[Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.](#)

Wang SH, Chi CC, Hu S.

Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Antidrug antibodies in psoriasis: A systematic review.](#)

Hsu L, Snodgrass BT, Armstrong AW.

Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.

Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.

Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: A systematic review of current evidence.](#)

Strohal R, Chimenti S, Vena GA, Girolomoni G.

J Dermatolog Treat. 2013 Jun;24(3):199-208. doi: 10.3109/09546634.2012.713462. Epub 2012 Nov 10.

[Impact of TNF- \$\alpha\$ antagonists on the quality of life in selected skin diseases.](#)

Gisondi P, Girolomoni G.

G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.

Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x. Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

[An evidence-based review of skin cancer rates on biologic therapies.](#)

Kamangar F, Neuhaus IM, Koo JY.

J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis.

Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, Li J, Baumgartner SW.

J Am Acad Dermatol. 2012 Aug;67(2):245-56. doi: 10.1016/j.jaad.2011.07.040. Epub 2011 Oct 19.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.

Brezinski EA, Armstrong AW.

PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Anti-TNF agents - infliximab

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.

[Epub ahead of print]

Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2017 Oct 27:1-28. doi: 10.1080/09546634.2017.1398393. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.
Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.

Yang ZS, Lin NN, Li L, Li Y.
Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

Review of maintenance of response to psoriasis treatments.

Bartos S, Hill D, Feldman SR.
J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

Systemic treatment of pediatric psoriasis: A review.

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

A systematic review on the efficacy and safety of infliximab in patients with psoriasis.

Wang J, Zhan Q, Zhang L.
Hum Vaccin Immunother. 2016;12(2):431-7. doi: 10.1080/21645515.2015.1081322.

Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

Systematic review on the maintenance of response during systemic antipsoriatic therapy.

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

Combining biologics with methotrexate in psoriasis: A systematic review.

van Bezooijen JS, Prens EP, Pradeepti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.
Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review.

Dannepond C, Maruani A, Machet L, Ternant D, Paintaud G, Samimi M.
Acta Derm Venereol. 2015 Apr;95(4):401-6. doi: 10.2340/00015555-1980.

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

Systemic treatments in paediatric psoriasis: A systematic evidence-based update.

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.
Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

Comparison of infliximab and ustekinumab for the treatment of moderate-to-severe psoriasis: An indirect comparison meta-analysis

Fan T, Bennett HA, Smith NE, Marin M, Sen SS.

Comparative Effectiveness Research 2015;5:1-11.

<https://www.dovepress.com/comparison-of-infliximab-and-ustekinumab-for-the-treatment-of-moderate-peer-reviewed-article-CER>

Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrández Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.
English, Spanish

Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.

Puig L, López A, Vilarrasa E, García I.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

Network meta-analysis of treatments for chronic plaque psoriasis in Canada.

Gupta AK, Daigle D, Lyons DC.

J Cutan Med Surg. 2014 Nov;18(6):371-8.

Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.

Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.
Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

Antidrug antibodies in psoriasis: A systematic review.

Hsu L, Snodgrass BT, Armstrong AW.
Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.

Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.

Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: Systematic review and meta-analysis.](#)

Maneiro JR, Salgado E, Gomez-Reino JJ.

JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.

[Meta-analysis: Rapid infliximab infusions are safe.](#)

Neef HC, Riebschleger MP, Adler J.

Aliment Pharmacol Ther. 2013 Aug;38(4):365-76. doi: 10.1111/apt.12389. Epub 2013 Jul 1.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Impact of TNF- \$\alpha\$ antagonists on the quality of life in selected skin diseases.](#)

Gisondi P, Girolomoni G.

G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.

Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[An evidence-based review of skin cancer rates on biologic therapies.](#)

Kamangar F, Neuhaus IM, Koo JY.

J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P. Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x. Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.

Brezinski EA, Armstrong AW.

PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Anti-TNF agents - adalimumab

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027. [Epub ahead of print]

[Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

[Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.](#)

Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.

Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2017 Oct 27:1-28. doi: 10.1080/09546634.2017.1398393. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.
J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.
Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.
Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.
Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.

Yang ZS, Lin NN, Li L, Li Y.
Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

Review of maintenance of response to psoriasis treatments.

Bartos S, Hill D, Feldman SR.
J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

Risk of serious infections in patients with psoriasis on biologic therapies: A systematic review and meta-analysis.

Yiu ZZ, Exton LS, Jabbar-Lopez Z, Mohd Mustapa MF, Samarasekera EJ, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Ashcroft DM, Griffiths CE, Smith CH, Warren RB.
J Invest Dermatol. 2016 Aug;136(8):1584-91. doi: 10.1016/j.jid.2016.03.035. Epub 2016 Apr 13.

Systemic treatment of pediatric psoriasis: A review.

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

Systematic review on the maintenance of response during systemic antipsoriatic therapy.

Jacobs A, Rosumeck S, Nast A.

Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.](#)

Gilbert KE, Manalo IF, Wu JJ.

J Am Acad Dermatol. 2015 Aug;73(2):329-31. doi: 10.1016/j.jaad.2015.04.012.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezoijen JS, Prens EP, Pradeepiti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.

Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.

J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.

Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.](#)

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

[Antidrug antibodies in psoriasis: A systematic review.](#)

Hsu L, Snodgrass BT, Armstrong AW.

Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrández Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E,

Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.
Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.
English, Spanish

[Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.](#)

Puig L, López A, Vilarrasa E, García I.
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.
J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.](#)

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.
Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

[Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.](#)

Wang SH, Chi CC, Hu S.
Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.
Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.
Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.
Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.
Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.](#)

Saraceno R, Bavetta M, Zangrilli A, Chiricozzi A, Potenza C, Chimenti S, Chimenti MS.
Expert Opin Biol Ther. 2013 Sep;13(9):1325-34. doi: 10.1517/14712598.2013.820701.

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: Systematic review and meta-analysis.

Maneiro JR, Salgado E, Gomez-Reino JJ.

JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.

Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

Impact of TNF- α antagonists on the quality of life in selected skin diseases.

Gisondi P, Girolomoni G.

G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP.

Ann Rheum Dis. 2013 Apr;72(4):517-24. doi: 10.1136/annrheumdis-2011-201244. Epub 2012 May 5.

Biological treatments for moderate-to-severe psoriasis: indirect comparison.

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.

Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

An evidence-based review of skin cancer rates on biologic therapies.

Kamangar F, Neuhaus IM, Koo JY.

J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.

Brezinski EA, Armstrong AW.

PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x.
Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Interleukin antagonists

Interleukin antagonists - general

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.
Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.
J Dermatolog Treat. 2018 Mar 13:1-37. doi: 10.1080/09546634.2017.1422591. [Epub ahead of print]

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.
Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.
J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.
[Epub ahead of print]

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.
Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.

No DJ, Amin M, Bhutani T, Wu JJ.
J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.

Théréné C, Brenaut E, Barnetche T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[\[A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis\].](#)

Fan XD, Xia X, Zhang CY, Kong WQ, Zhou CY, DU B.

Nan Fang Yi Ke Da Xue Xue Bao. 2017 Sep 20;37(9):1274-1279. Chinese.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.

Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: A meta-analysis from phase 3 randomized controlled trials.](#)

Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. Epub 2017 Feb 8.

[Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.](#)

Saunte DM, Mrowietz U, Puig L, Zachariae C.

Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.

[No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.](#)

Chiricozzi A, Romanelli M, Saraceno R, Torres T.

Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659. Epub 2016 Aug 31.

[Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.](#)

Chen Y, Qian T, Zhang D, Yan H, Hao F.

Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.

[Anti-IL-17 phase II data for psoriasis: A review.](#)

Brown G, Malakouti M, Wang E, Koo JY, Levin E.

J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20.

[Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials.](#)

Tzellos T, Kyrgidis A, Zouboulis CC.

J Eur Acad Dermatol Venereol. 2013 May;27(5):622-7. doi: 10.1111/j.1468-3083.2012.04500.x. Epub 2012 Mar 8.

Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.
Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

An evidence-based review of skin cancer rates on biologic therapies.

Kamangar F, Neuhaus IM, Koo JY.
J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

Interleukin antagonists – ustekinumab (IL-12/23 inhibitor)

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.
Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.
Cutis. 2018 Jan;101(1):38;42;56.

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.
J Dermatolog Treat. 2018 Mar 13:1-37. doi: 10.1080/09546634.2017.1422591. [Epub ahead of print]

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.
Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.
J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.
[Epub ahead of print]

Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.

Kromer C, Celis D, Sonntag D, Peitsch WK.
PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.
Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

[Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.](#)

Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.

Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2017 Oct 27:1-28. doi: 10.1080/09546634.2017.1398393. [Epub ahead of print]

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatorta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[Risk of cancer in patients with psoriasis on biologic therapies: A systematic review.](#)

Peleva E, Exton LS, Kelley K, Mason KJ, Smith CH.

Br J Dermatol. 2018 Jan;178(1):103-113. doi: 10.1111/bjd.15830. Epub 2017 Dec 18.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasakera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.

Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lü mig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.

Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.

Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.

J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.

Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P. Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

Comparison of infliximab and ustekinumab for the treatment of moderate-to-severe psoriasis: An indirect comparison meta-analysis

Fan T, Bennett HA, Smith NE, Marin M, Sen SS.

Comparative Effectiveness Research 2015;5:1-11.

<https://www.dovepress.com/comparison-of-infliximab-and-ustekinumab-for-the-treatment-of-moderate-peer-reviewed-article-CER>

Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrández Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19. English, Spanish

Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.

Puig L, López A, Vilarrasa E, García I.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

Network meta-analysis of treatments for chronic plaque psoriasis in Canada.

Gupta AK, Daigle D, Lyons DC.

J Cutan Med Surg. 2014 Nov;18(6):371-8.

Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.

Wang SH, Chi CC, Hu S.

Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis.

Meng Y, Dongmei L, Yanbin P, Jinju F, Meile T, Binzhu L, Xiao H, Ping T, Jianmin L.

Clin Exp Dermatol. 2014 Aug;39(6):696-707. doi: 10.1111/ced.12390.

Therapeutic effect and safety of ustekinumab for plaque psoriasis: A meta-analysis.

Liu Y, Gong JP, Li WF.

Chin Med Sci J. 2014 Sep;29(3):131-8.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

Antidrug antibodies in psoriasis: A systematic review.

Hsu L, Snodgrass BT, Armstrong AW.
Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.
Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.
Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.
J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials.](#)
Tzellos T, Kyrgidis A, Zouboulis CC.
J Eur Acad Dermatol Venereol. 2013 May;27(5):622-7. doi: 10.1111/j.1468-3083.2012.04500.x. Epub 2012 Mar 8.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.
J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A Bayesian network meta-analysis.](#)

Lin VW, Ringold S, Devine EB.
Arch Dermatol. 2012 Dec;148(12):1403-10. doi: 10.1001/2013.jamadermatol.238.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.
Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.
J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x.
Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P. Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.

Brezinski EA, Armstrong AW. PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS. Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Treatment of psoriasis with interleukin-12/23 monoclonal antibody: A systematic review.

Wu Y, Chen J, Li YH, Ma GZ, Chen JZ, Gao XH, Chen HD. Eur J Dermatol. 2012 Jan-Feb;22(1):72-82. doi: 10.1684/ejd.2011.1559.

Interleukin antagonists – secukinumab (IL-17 inhibitor)

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ. Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. J Dermatolog Treat. 2018 Mar 13:1-37. doi: 10.1080/09546634.2017.1422591. [Epub ahead of print]

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P. Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA. J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027. [Epub ahead of print]

Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.

Kromer C, Celis D, Sonntag D, Peitsch WK. PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[\[A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis\].](#)

Fan XD, Xia X, Zhang CY, Kong WQ, Zhou CY, DU B.

Nan Fang Yi Ke Da Xue Xue Bao. 2017 Sep 20;37(9):1274-1279. Chinese.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.

Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: A meta-analysis from phase 3 randomized controlled trials.](#)

Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. Epub 2017 Feb 8.

No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.

Chiricozzi A, Romanelli M, Saraceno R, Torres T.

Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659. Epub 2016 Aug 31.

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.

Saunte DM, Mrowietz U, Puig L, Zachariae C.

Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.

Review of maintenance of response to psoriasis treatments.

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis.

topical treatments for scalp psoriasis JY, Yang HJ, Ji E, Yoo BK.

Ann Pharmacother. 2016 May;50(5):341-51. doi: 10.1177/1060028015626545. Epub 2016 Jan 18.

Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.

Chen Y, Qian T, Zhang D, Yan H, Hao F.

Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.

Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials.

Xiong HZ, Gu JY, He ZG, Chen WJ, Zhang X, Wang JY, Shi YL.

Int J Clin Exp Med. 2015 Mar 15;8(3):3156-72. eCollection 2015.

Anti-IL-17 phase II data for psoriasis: A review.

Brown G, Malakouti M, Wang E, Koo JY, Levin E.

J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20.

Interleukin antagonists - ixekizumab (IL-17 inhibitor)

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Mar 13:1-37. doi: 10.1080/09546634.2017.1422591. [Epub ahead of print]

[\[EXPRESS\] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.
Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.
J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.
[Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.
Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.
J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[\[A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis\].](#)

Fan XD, Xia X, Zhang CY, Kong WQ, Zhou CY, DU B.
Nan Fang Yi Ke Da Xue Xue Bao. 2017 Sep 20;37(9):1274-1279. Chinese.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.
J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.
Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: A meta-analysis from phase 3 randomized controlled trials.

Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. Epub 2017 Feb 8.

No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.

Chiricozzi A, Romanelli M, Saraceno R, Torres T.

Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659. Epub 2016 Aug 31.

Review of maintenance of response to psoriasis treatments.

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.

Saunte DM, Mrowietz U, Puig L, Zachariae C.

Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.

Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.

Chen Y, Qian T, Zhang D, Yan H, Hao F.

Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.

Anti-IL-17 phase II data for psoriasis: A review.

Brown G, Malakouti M, Wang E, Koo JY, Levin E.

J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20.

Interleukin antagonists - brodalumab (IL-17 inhibitor)

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Mar 13:1-37. doi: 10.1080/09546634.2017.1422591. [Epub ahead of print]

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027. [Epub ahead of print]

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.

Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Møller A.
J Dermatolog Treat. 2018 Jan 11:1-39. doi: 10.1080/09546634.2018.1427205. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)
Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.
Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.
J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[\[A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis\].](#)

Fan XD, Xia X, Zhang CY, Kong WQ, Zhou CY, DU B.
Nan Fang Yi Ke Da Xue Xue Bao. 2017 Sep 20;37(9):1274-1279. Chinese.

[Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Attia A, Abushouk AI, Ahmed H, Gadelkarim M, Elgebaly A, Hassan Z, Abdel-Daim MM, Negida A.
Clin Drug Investig. 2017 May;37(5):439-451. doi: 10.1007/s40261-017-0500-9.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.
Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: A meta-analysis from phase 3 randomized controlled trials.](#)

Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N.
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. Epub 2017 Feb 8.

[No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.](#)

Chiricozzi A, Romanelli M, Saraceno R, Torres T.
Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659. Epub 2016 Aug 31.

[Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.](#)

Saunte DM, Mrowietz U, Puig L, Zachariae C.

Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.

Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.

Chen Y, Qian T, Zhang D, Yan H, Hao F.

Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.

Anti-IL-17 phase II data for psoriasis: A review.

Brown G, Malakouti M, Wang E, Koo JY, Levin E.

J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20.

Interleukin antagonists - guselkumab (IL-23 inhibitor)

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Mar 13:1-37. doi: 10.1080/09546634.2017.1422591. [Epub ahead of print]

[EXPRESS] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

Treating moderate-to-severe plaque psoriasis with guselkumab: a review of phase II and phase III trials.

Howell ST, Cardwell LA, Feldman SR.

Ann Pharmacother. 2018 Apr;52(4):380-387. doi: 10.1177/1060028017743268. Epub 2017 Nov 14.

A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.

Amin M, Darji K, No DJ, Wu JJ.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1627-1632. doi: 10.1111/jdv.14451. Epub 2017 Jul 17.

Interleukin antagonists - tildrakizumab (IL-23 inhibitor)

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Mar 13:1-37. doi: 10.1080/09546634.2017.1422591. [Epub ahead of print]

[\[EXPRESS\] quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan 1:1744806918762205. doi: 10.1177/1744806918762205. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2017 Nov 6:1-28. doi: 10.1080/09546634.2017.1402116. [Epub ahead of print]

[Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.](#)

Amin M, Darji K, No DJ, Wu JJ.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1627-1632. doi: 10.1111/jdv.14451. Epub 2017 Jul 17.

New small molecule systemic therapies

Small molecule systemic therapies – general

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.
[Epub ahead of print]

Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

Review of maintenance of response to psoriasis treatments.

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

Phosphodiesterase-4 inhibitors - apremilast

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Apr 5:1-17. doi: 10.1080/03007995.2018.1457516. [Epub ahead of print]

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027.

[Epub ahead of print]

[Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Apremilast: A novel drug for treatment of psoriasis and psoriatic arthritis.](#)

Haber SL, Hamilton S, Bank M, Leong SY, Pierce E.

Ann Pharmacother. 2016 Apr;50(4):282-90. doi: 10.1177/1060028015627467. Epub 2016 Jan 18.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Apremilast for the treatment of psoriasis.](#)

Chimenti MS, Gramiccia T, Saraceno R, Bianchi L, Garofalo V, Buonomo O, Perricone R, Chimenti S, Chiricozzi A.

Expert Opin Pharmacother. 2015;16(13):2083-94. Epub 2015 Aug 4

Janus kinase inhibitors - general

Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

Janus kinase inhibitors in dermatology: A systematic review.

Shreberk-Hassidim R, Ramot Y, Zlotogorski A.

J Am Acad Dermatol. 2017 Apr;76(4):745-753.e19. doi: 10.1016/j.jaad.2016.12.004. Epub 2017 Feb 4.

Janus kinase inhibitors - tofacitinib

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.

Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.

Kuo CM, Tung TH, Wang SH, Chi CC.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):355-362. doi: 10.1111/jdv.14695. Epub 2017 Dec 5.

Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.

Théréné C, Brenaut E, Barnetche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

Janus kinase inhibitors in dermatology: A systematic review.

Shreberk-Hassidim R, Ramot Y, Zlotogorski A.

J Am Acad Dermatol. 2017 Apr;76(4):745-753.e19. doi: 10.1016/j.jaad.2016.12.004. Epub 2017 Feb 4.

Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

Combination therapies

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.](#)

Koo K, Jeon C, Bhutani T.

J Dermatolog Treat. 2017 Dec;28(8):702-708. doi: 10.1080/09546634.2017.1328098. Epub 2017 Jun 6.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepiti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.

Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Combined use of systemic agents for psoriasis: A systematic review.](#)

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.

JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Combination therapy in psoriasis: An evidence-based review.](#)

Gustafson CJ, Watkins C, Hix E, Feldman SR.

Am J Clin Dermatol. 2013 Feb;14(1):9-25. doi: 10.1007/s40257-012-0003-7.

[Combination treatments for psoriasis: A systematic review and meta-analysis.](#)

Bailey EE, Ference EH, Alikhan A, Hession MT, Armstrong AW.

Arch Dermatol. 2012 Apr;148(4):511-22. doi: 10.1001/archdermatol.2011.1916. Epub 2011 Dec 19.

Other treatments

Psychological & educational interventions

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Education to improve quality of life of people with chronic inflammatory skin conditions: A systematic review of the evidence.](#)

Pickett K, Frampton G, Loveman E.

Br J Dermatol. 2016 Jun;174(6):1228-41. doi: 10.1111/bjd.14435. Epub 2016 Apr 28.

[Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations.](#)

Nyssen OP, Taylor SJ, Wong G, Steed E, Bourke L, Lord J, Ross CA, Hayman S, Field V, Higgins A, Greenhalgh T, Meads C.

Health Technol Assess. 2016 Apr;20(27):vii-xxxvii, 1-367. doi: 10.3310/hta20270.

[Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: Systematic reviews of clinical effectiveness and cost-effectiveness.](#)

Pickett K, Loveman E, Kalita N, Frampton GK, Jones J.

Health Technol Assess. 2015 Oct;19(86):1-176, v-vi. doi: 10.3310/hta19860.

[Limited evidence of the effects of patient education and self-management interventions in psoriasis patients: A systematic review.](#)

Larsen MH, Hagen KB, Krogstad AL, Aas E, Wahl AK.

Patient Educ Couns. 2014 Feb;94(2):158-69. doi: 10.1016/j.pec.2013.10.005. Epub 2013 Oct 14.

[Evaluating the effectiveness of psychological and/or educational interventions in psoriasis: A narrative review.](#)

Chen Y, Xin T, Cheng AS.

J Dermatol. 2014 Sep;41(9):775-8. doi: 10.1111/1346-8138.12583. Epub 2014 Aug 11.

[Can stress reduction interventions improve psoriasis? A review.](#)

Fordham B, Griffiths CE, Bundy C.

Psychol Health Med. 2013;18(5):501-14. doi: 10.1080/13548506.2012.736625. Epub 2012 Nov 2.

[A systematic review of self-help for disfigurement: effectiveness, usability, and acceptability.](#)

Muftin Z, Thompson AR.

Body Image. 2013 Sep;10(4):442-50. doi: 10.1016/j.bodyim.2013.07.005. Epub 2013 Aug 17.

Weight loss

[Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: A systematic review and meta-analysis.](#)

Upala S, Sanguankeo A.

Int J Obes (Lond). 2015 Aug;39(8):1197-202. doi: 10.1038/ijo.2015.64. Epub 2015 Apr 29.

[Diet and psoriasis, part I: Impact of weight loss interventions.](#)

Debbaneh M, Millsop JW, Bhatia BK, Koo J, Liao W.
J Am Acad Dermatol. 2014 Jul;71(1):133-40. doi: 10.1016/j.jaad.2014.02.012. Epub 2014 Apr 4.

Diet & supplements

Probiotics, prebiotics, and synbiotics for the treatment and prevention of adult dermatological diseases.

Notay M, Foolad N, Vaughn AR, Sivamani RK.
Am J Clin Dermatol. 2017 Dec;18(6):721-732. doi: 10.1007/s40257-017-0300-2.

Diet and psoriasis, part II: Celiac disease and role of a gluten-free diet.

Bhatia BK, Millsop JW, Debbaneh M, Koo J, Linos E, Liao W.
J Am Acad Dermatol. 2014 Aug;71(2):350-8. doi: 10.1016/j.jaad.2014.03.017. Epub 2014 Apr 26.

Diet and psoriasis, part III: Role of nutritional supplements.

Millsop JW, Bhatia BK, Debbaneh M, Koo J, Liao W.
J Am Acad Dermatol. 2014 Sep;71(3):561-9. doi: 10.1016/j.jaad.2014.03.016. Epub 2014 Apr 26.

Tonsillectomy

Indications for tonsillectomy stratified by the level of evidence.

Windfuhr JP.
GMS Curr Top Otorhinolaryngol Head Neck Surg. 2016 Dec 15;15:Doc09. doi: 10.3205/cto000136.
eCollection 2016.

[Evidence-based Indications for Tonsillectomy].

Windfuhr JP.
Laryngorhinootologie. 2016 Apr;95 Suppl 1:S38-87. doi: 10.1055/s-0041-109590. Epub 2016 Apr 29.
German.

Effect of tonsillectomy on psoriasis: A systematic review.

Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW.
J Am Acad Dermatol. 2015 Feb;72(2):261-75. doi: 10.1016/j.jaad.2014.10.013. Epub 2014 Nov 20.

Antistreptococcal interventions for guttate and chronic plaque psoriasis.

Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE.
Cochrane Database Syst Rev. 2000;(2):CD001976.

Herbal medicine (including Chinese herbal medicine)

Topical botanical agents for the treatment of psoriasis: A systematic review.

Farahnik B, Sharma D, Alban J, Sivamani RK.
Am J Clin Dermatol. 2017 Aug;18(4):451-468. doi: 10.1007/s40257-017-0266-0.

Effectiveness and safety of traditional Chinese medical bath therapy combined with ultraviolet irradiation in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.

Guan J, Yuan S, Wu H, Na R, Wu X, Wang X, Bao S.

PLoS One. 2017 Mar 21;12(3):e0173276. doi: 10.1371/journal.pone.0173276. eCollection 2017.

Oral (systemic) botanical agents for the treatment of psoriasis: A review.

Farahnik B, Sharma D, Alban J, Sivamani R.

J Altern Complement Med. 2017 Jun;23(6):418-425. doi: 10.1089/acm.2016.0324. Epub 2017 Feb 3.

Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review.

Parker S, Zhang CS, Yu JJ, Lu C, Zhang AL, Xue CC.

J Dermatolog Treat. 2017 Feb;28(1):21-31. doi: 10.1080/09546634.2016.1178377. Epub 2016 Jul 1.

Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: A systematic review and meta-analysis of randomized controlled trials.

Yu JJ, Zhang CS, Coyle ME, Du Y, Zhang AL, Guo X, Xue CC, Lu C.

Curr Med Res Opin. 2017 Feb;33(2):279-287. doi: 10.1080/03007995.2016.1254605. Epub 2016 Nov 10.

Effects of turmeric (*Curcuma longa*) on skin health: A systematic review of the clinical evidence.

Vaughn AR, Branum A, Sivamani RK.

Phytother Res. 2016 Aug;30(8):1243-64. doi: 10.1002/ptr.5640. Epub 2016 May 23.

Is oral Chinese herbal medicine beneficial for psoriasis vulgaris? A meta-analysis of comparisons with acitretin.

Zhang CS, Yang L, Zhang AL, May BH, Yu JJ, Guo X, Lu C, Xue CC.

J Altern Complement Med. 2016 Mar;22(3):174-88. doi: 10.1089/acm.2014.0212. Epub 2016 Feb 26.

Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: A systematic review and meta-analysis.

Yang L, Zhang CS, May B, Yu J, Guo X, Zhang AL, Xue CC, Lu C.

Chin Med. 2015 Sep 26;10:27. doi: 10.1186/s13020-015-0060-y. eCollection 2015.

Review of clinical pharmacology of Aloe vera L. in the treatment of psoriasis.

Miroddi M, Navarra M, Calapai F, Mancari F, Giofrè SV, Gangemi S, Calapai G.

Phytother Res. 2015 May;29(5):648-55. doi: 10.1002/ptr.5316. Epub 2015 Mar 10.

Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: A systematic review.

Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, Xue CC.

Int J Dermatol. 2014 Nov;53(11):1305-18. doi: 10.1111/ijd.12607. Epub 2014 Sep 10.

Topical herbal formulae in the management of psoriasis: Systematic review with meta-analysis of clinical studies and investigation of the pharmacological actions of the main herbs.

Deng S, May BH, Zhang AL, Lu C, Xue CC.

Phytother Res. 2014 Apr;28(4):480-97. doi: 10.1002/ptr.5028. Epub 2013 Jul 1.

Plant extracts for the topical management of psoriasis: A systematic review and meta-analysis.

Deng S, May BH, Zhang AL, Lu C, Xue CC.

Br J Dermatol. 2013 Oct;169(4):769-82. doi: 10.1111/bjd.12557

Add-on effect of Chinese herbal medicine bath to phototherapy for psoriasis vulgaris: A systematic review.

Yu JJ, Zhang CS, Zhang AL, May B, Xue CC, Lu C.

Evid Based Complement Alternat Med. 2013;2013:673078. doi: 10.1155/2013/673078. Epub 2013 Jul 25.

[Topical herbal medicine combined with pharmacotherapy for psoriasis: A systematic review and meta-analysis.](#)

Deng S, May BH, Zhang AL, Lu C, Xue CC.

Arch Dermatol Res. 2013 Apr;305(3):179-89. doi: 10.1007/s00403-013-1316-y. Epub 2013 Jan 26.

[Efficacy of externally applied Chinese herbal drugs in treating psoriasis: A systematic review.](#)

Li N, Li YQ, Li HY, Guo W, Bai YP.

Chin J Integr Med. 2012 Mar;18(3):222-9. doi: 10.1007/s11655-012-1004-3. Epub 2012 Apr 2.

[Oral herbal medicines for psoriasis: A review of clinical studies.](#)

May BH, Zhang AL, Zhou W, Lu CJ, Deng S, Xue CC.

Chin J Integr Med. 2012 Mar;18(3):172-8. doi: 10.1007/s11655-012-1008-z. Epub 2012 Apr 2.

Other complementary & alternative therapies

[Acupuncture-related techniques for psoriasis: A systematic review with pairwise and network meta-analyses of randomized controlled trials.](#)

Yeh ML, Ko SH, Wang MH, Chi CC, Chung YC.

J Altern Complement Med. 2017 Dec;23(12):930-940. doi: 10.1089/acm.2016.0158. Epub 2017 Jun 19.

[Immune signatures in patients with psoriasis vulgaris of blood-heat syndrome: A systematic review and meta-analysis.](#)

Li X, Xiao QQ, Li FL, Xu R, Fan B, Wu MF, Zhou M, Li S, Chen J, Peng SG, Li B.

Evid Based Complement Alternat Med. 2016;2016:9503652. doi: 10.1155/2016/9503652. Epub 2016 May 4.

[Acupuncture therapies for psoriasis vulgaris: A systematic review of randomized controlled trials.](#)

Coyle M, Deng J, Zhang AL, Yu J, Guo X, Xue CC, Lu C.

Forsch Komplementmed. 2015;22(2):102-9. doi: 10.1159/000381225. Epub 2015 Mar 20.

[Scientific evidence of the therapeutic effects of Dead Sea treatments: A systematic review.](#)

Katz U, Shoenfeld Y, Zakin V, Sherer Y, Sukenik S.

Semin Arthritis Rheum. 2012 Oct;42(2):186-200. doi: 10.1016/j.semarthrit.2012.02.006. Epub 2012 Apr 12.